https://trial.medpath.com/news/the-340b-drug-pricing-program-how-a-safety-net-initiative-became-an-81-billion-flashpoint 2026-06-17T09:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-340b-drug-pricing-program-how-a-safety-net-initiative-became-an-81-billion-flashpoint 2026-06-17T09:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/2026-acc-aha-guideline-introduces-five-tier-risk-stratification-for-acute-pulmonary-embolism-refining-role-of-catheter-based-interventions 2026-06-17T09:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-acc-aha-guideline-introduces-five-tier-risk-stratification-for-acute-pulmonary-embolism-refining-role-of-catheter-based-interventions 2026-06-17T09:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-bayesian-guidance-promises-trial-efficiency-gains-but-sites-face-unprepared-infrastructure 2026-06-17T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-bayesian-guidance-promises-trial-efficiency-gains-but-sites-face-unprepared-infrastructure 2026-06-17T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/addressing-sexual-dysfunction-after-cancer-treatment-breaking-the-silence-in-oncology-care 2026-06-17T08:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addressing-sexual-dysfunction-after-cancer-treatment-breaking-the-silence-in-oncology-care 2026-06-17T08:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-study-uncovers-r-loop-export-as-driver-of-inflammaging-points-to-fda-approved-selinexor-as-potential-treatment 2026-06-17T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-study-uncovers-r-loop-export-as-driver-of-inflammaging-points-to-fda-approved-selinexor-as-potential-treatment 2026-06-17T08:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-cells-and-cell-derived-products-charting-the-next-frontier-in-tissue-defect-repair 2026-06-17T08:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-cells-and-cell-derived-products-charting-the-next-frontier-in-tissue-defect-repair 2026-06-17T08:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-advocacy-emerges-as-critical-front-in-the-fight-against-antimicrobial-resistance 2026-06-17T07:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-advocacy-emerges-as-critical-front-in-the-fight-against-antimicrobial-resistance 2026-06-17T07:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-retinal-scans-may-unlock-early-detection-of-heart-and-brain-disease-two-landmark-studies-show 2026-06-17T06:10:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-retinal-scans-may-unlock-early-detection-of-heart-and-brain-disease-two-landmark-studies-show 2026-06-17T06:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/karnataka-charts-ai-driven-biotechnology-roadmap-at-64th-vision-group-meeting 2026-06-17T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karnataka-charts-ai-driven-biotechnology-roadmap-at-64th-vision-group-meeting 2026-06-17T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/trump-era-research-policies-drive-young-biomedical-scientists-away-from-academia-and-the-u-s-survey-finds 2026-06-17T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-era-research-policies-drive-young-biomedical-scientists-away-from-academia-and-the-u-s-survey-finds 2026-06-17T06:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/women-s-brains-may-be-more-vulnerable-to-dementia-risk-factors-landmark-study-reveals 2026-06-17T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/women-s-brains-may-be-more-vulnerable-to-dementia-risk-factors-landmark-study-reveals 2026-06-17T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/towa-pharmaceutical-recalls-duloxetine-over-nitrosamine-impurity-fda-classifies-as-class-ii-recall 2026-06-17T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/towa-pharmaceutical-recalls-duloxetine-over-nitrosamine-impurity-fda-classifies-as-class-ii-recall 2026-06-17T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/universities-and-hospitals-repurpose-generic-drugs-through-late-stage-trials-at-90-lower-cost-than-industry 2026-06-17T04:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/universities-and-hospitals-repurpose-generic-drugs-through-late-stage-trials-at-90-lower-cost-than-industry 2026-06-17T04:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/formestane-endogenous-research-raises-integrity-questions-in-australian-horse-racing 2026-06-17T04:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formestane-endogenous-research-raises-integrity-questions-in-australian-horse-racing 2026-06-17T04:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-reports-positive-preliminary-phase-1-data-for-il-2-fusion-immunotherapeutic-hcw9302-in-alopecia-areata 2026-06-17T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-reports-positive-preliminary-phase-1-data-for-il-2-fusion-immunotherapeutic-hcw9302-in-alopecia-areata 2026-06-17T04:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-hit-by-major-cyberattack-fulcrumsec-leaks-1-3tb-of-stolen-data-including-clinical-trial-records-and-ai-models 2026-06-17T04:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-hit-by-major-cyberattack-fulcrumsec-leaks-1-3tb-of-stolen-data-including-clinical-trial-records-and-ai-models 2026-06-17T04:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/acog-breaks-from-cdc-issues-independent-maternal-immunization-schedule-amid-federal-policy-shift 2026-06-17T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acog-breaks-from-cdc-issues-independent-maternal-immunization-schedule-amid-federal-policy-shift 2026-06-17T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/eu-adopts-two-tier-regulatory-framework-for-gene-edited-crops-opening-new-path-for-crispr-innovation 2026-06-17T04:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-adopts-two-tier-regulatory-framework-for-gene-edited-crops-opening-new-path-for-crispr-innovation 2026-06-17T04:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/laboratory-robotics-market-poised-to-reach-5-12-billion-by-2034-driven-by-ai-integration-and-precision-medicine 2026-06-17T03:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laboratory-robotics-market-poised-to-reach-5-12-billion-by-2034-driven-by-ai-integration-and-precision-medicine 2026-06-17T03:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-omega-3s-and-diet-shift-next-generation-epigenetic-aging-clocks-in-human-studies 2026-06-17T03:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-omega-3s-and-diet-shift-next-generation-epigenetic-aging-clocks-in-human-studies 2026-06-17T03:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/the-vaccine-revolution-in-oncology-is-finally-here-neoantigens-lnps-and-the-new-paradigm 2026-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-vaccine-revolution-in-oncology-is-finally-here-neoantigens-lnps-and-the-new-paradigm 2026-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-alzheimer-s-disease-treatment-from-anti-amyloid-antibodies-to-multi-target-strategies 2026-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-alzheimer-s-disease-treatment-from-anti-amyloid-antibodies-to-multi-target-strategies 2026-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/penn-state-expands-natural-product-research-from-cannabis-to-ghost-pipe-the-push-for-evidence-based-plant-medicine 2026-06-16T23:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-state-expands-natural-product-research-from-cannabis-to-ghost-pipe-the-push-for-evidence-based-plant-medicine 2026-06-16T23:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-foundation-unveils-strategic-roadmap-to-revitalize-regenerative-medicine-in-europe 2026-06-16T23:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-foundation-unveils-strategic-roadmap-to-revitalize-regenerative-medicine-in-europe 2026-06-16T23:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/steer-health-wins-2026-hearst-health-prize-for-ai-powered-clinical-orchestration-dana-farber-s-matchminer-named-finalist 2026-06-16T23:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steer-health-wins-2026-hearst-health-prize-for-ai-powered-clinical-orchestration-dana-farber-s-matchminer-named-finalist 2026-06-16T23:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-advances-mrna-pipeline-with-multiple-phase-2-rare-disease-programs-and-self-amplifying-rna-vaccine-platform 2026-06-16T23:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-advances-mrna-pipeline-with-multiple-phase-2-rare-disease-programs-and-self-amplifying-rna-vaccine-platform 2026-06-16T23:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/brain-implant-trial-renews-hope-for-stroke-survivors-uw-medicine-reports-life-changing-motor-recovery 2026-06-16T22:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-implant-trial-renews-hope-for-stroke-survivors-uw-medicine-reports-life-changing-motor-recovery 2026-06-16T22:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/sun-life-and-medzown-partner-to-expand-clinical-trial-access-for-cancer-and-complex-diseases 2026-06-16T22:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-life-and-medzown-partner-to-expand-clinical-trial-access-for-cancer-and-complex-diseases 2026-06-16T22:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-cell-study-identifies-rock2-as-precision-target-tdi01-demonstrates-liver-fibrosis-reversal-in-early-clinical-data 2026-06-16T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-cell-study-identifies-rock2-as-precision-target-tdi01-demonstrates-liver-fibrosis-reversal-in-early-clinical-data 2026-06-16T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/immune-receptor-a2ar-plays-paradoxical-dual-role-in-t-cell-exhaustion-challenging-checkpoint-therapy-assumptions 2026-06-16T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-receptor-a2ar-plays-paradoxical-dual-role-in-t-cell-exhaustion-challenging-checkpoint-therapy-assumptions 2026-06-16T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/photosynthetic-eye-drops-derived-from-spinach-reverse-corneal-damage-in-preclinical-dry-eye-model 2026-06-16T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/photosynthetic-eye-drops-derived-from-spinach-reverse-corneal-damage-in-preclinical-dry-eye-model 2026-06-16T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/japac-emerges-as-a-global-accelerator-for-clinical-development-as-sponsors-seek-to-overcome-enrollment-delays 2026-06-16T20:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japac-emerges-as-a-global-accelerator-for-clinical-development-as-sponsors-seek-to-overcome-enrollment-delays 2026-06-16T20:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/corvus-pharmaceuticals-approaches-pivotal-soquelitinib-phase-2-data-readout-amid-m-a-speculation 2026-06-16T20:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-approaches-pivotal-soquelitinib-phase-2-data-readout-amid-m-a-speculation 2026-06-16T20:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gut-brain-drug-nezavist-shows-promise-for-alcohol-use-disorder-enters-phase-1-trials 2026-06-16T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gut-brain-drug-nezavist-shows-promise-for-alcohol-use-disorder-enters-phase-1-trials 2026-06-16T19:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/amivantamab-shows-preclinical-immune-mediated-activity-in-mesothelioma-through-dual-egfr-met-targeting 2026-06-16T19:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amivantamab-shows-preclinical-immune-mediated-activity-in-mesothelioma-through-dual-egfr-met-targeting 2026-06-16T19:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-reports-402-marine-toxin-outbreaks-in-the-u-s-over-13-years-scombroid-and-ciguatoxin-dominate 2026-06-16T19:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-reports-402-marine-toxin-outbreaks-in-the-u-s-over-13-years-scombroid-and-ciguatoxin-dominate 2026-06-16T19:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/3d-multi-omics-tumour-atlases-from-technology-to-clinical-translation 2026-06-16T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-multi-omics-tumour-atlases-from-technology-to-clinical-translation 2026-06-16T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ehr-based-marker-identifies-pediatric-liver-transplant-patients-at-high-risk-for-organ-rejection 2026-06-16T19:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ehr-based-marker-identifies-pediatric-liver-transplant-patients-at-high-risk-for-organ-rejection 2026-06-16T19:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/12-gene-presymptomatic-signature-and-vulnerable-trilaminar-interneurons-uncovered-in-early-rett-syndrome 2026-06-16T19:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/12-gene-presymptomatic-signature-and-vulnerable-trilaminar-interneurons-uncovered-in-early-rett-syndrome 2026-06-16T19:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-awarded-1-1m-nih-grant-to-study-pfas-exposure-and-metabolic-health-in-children 2026-06-16T18:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainehealth-awarded-1-1m-nih-grant-to-study-pfas-exposure-and-metabolic-health-in-children 2026-06-16T18:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/the-cro-isn-t-failing-your-trial-your-governance-model-is 2026-06-16T18:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-cro-isn-t-failing-your-trial-your-governance-model-is 2026-06-16T18:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-agnostic-basket-trials-open-clinical-trial-access-for-rare-cancers-led-by-larotrectinib-success-in-cifs 2026-06-16T18:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-agnostic-basket-trials-open-clinical-trial-access-for-rare-cancers-led-by-larotrectinib-success-in-cifs 2026-06-16T18:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/from-ground-zero-to-oncology-care-a-daiichi-sankyo-leader-s-journey 2026-06-16T17:12:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-ground-zero-to-oncology-care-a-daiichi-sankyo-leader-s-journey 2026-06-16T17:12:05+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-elevates-2026-ebola-outbreak-to-level-1-emergency-response-amid-severe-staffing-shortages 2026-06-16T17:11:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-elevates-2026-ebola-outbreak-to-level-1-emergency-response-amid-severe-staffing-shortages 2026-06-16T17:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-launches-2-04-million-digital-stockpile-manufacturing-response-network-challenge 2026-06-16T17:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-launches-2-04-million-digital-stockpile-manufacturing-response-network-challenge 2026-06-16T17:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/the-billionaire-biohacking-paradox-why-self-experimentation-cannot-replace-clinical-trials-in-longevity-science 2026-06-16T17:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-billionaire-biohacking-paradox-why-self-experimentation-cannot-replace-clinical-trials-in-longevity-science 2026-06-16T17:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-secures-uae-ind-approval-for-neo212-advancing-oral-brain-cancer-therapy-toward-global-phase-2-development 2026-06-16T17:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-secures-uae-ind-approval-for-neo212-advancing-oral-brain-cancer-therapy-toward-global-phase-2-development 2026-06-16T17:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-shows-promise-for-reversing-gray-hair-from-cancer-side-effect-to-potential-treatment 2026-06-16T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-shows-promise-for-reversing-gray-hair-from-cancer-side-effect-to-potential-treatment 2026-06-16T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-s-heng-yi-wins-nmpa-approval-as-china-s-first-water-free-cyclosporine-ophthalmic-solution-for-dry-eye-disease 2026-06-16T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-s-heng-yi-wins-nmpa-approval-as-china-s-first-water-free-cyclosporine-ophthalmic-solution-for-dry-eye-disease 2026-06-16T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/biomimetic-polymer-nanomaterials-reprogram-the-immunosuppressive-microenvironment-in-hepatocellular-carcinoma 2026-06-16T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomimetic-polymer-nanomaterials-reprogram-the-immunosuppressive-microenvironment-in-hepatocellular-carcinoma 2026-06-16T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/higher-vitamin-c-levels-linked-to-preserved-brain-structure-and-connectivity-in-older-adults-large-japanese-study-finds 2026-06-16T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-vitamin-c-levels-linked-to-preserved-brain-structure-and-connectivity-in-older-adults-large-japanese-study-finds 2026-06-16T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/wait-times-beyond-68-days-for-sentinel-node-biopsy-linked-to-worse-melanoma-survival-in-the-adjuvant-therapy-era 2026-06-16T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wait-times-beyond-68-days-for-sentinel-node-biopsy-linked-to-worse-melanoma-survival-in-the-adjuvant-therapy-era 2026-06-16T16:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-acquires-4e-therapeutics-to-advance-non-opioid-mnk-inhibitor-pipeline-for-chronic-pain 2026-06-16T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-acquires-4e-therapeutics-to-advance-non-opioid-mnk-inhibitor-pipeline-for-chronic-pain 2026-06-16T16:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/pew-charitable-trusts-names-21-new-biomedical-scholars-for-2026-backing-early-career-research-from-cancer-vaccines-to-neuroregeneration 2026-06-16T16:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pew-charitable-trusts-names-21-new-biomedical-scholars-for-2026-backing-early-career-research-from-cancer-vaccines-to-neuroregeneration 2026-06-16T16:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/india-ends-over-the-counter-sale-of-syrups-mandates-prescriptions-amid-safety-concerns 2026-06-16T16:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-ends-over-the-counter-sale-of-syrups-mandates-prescriptions-amid-safety-concerns 2026-06-16T16:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/trilink-opens-gmp-enzyme-manufacturing-facility-ships-first-commercial-batch-to-streamline-rna-therapeutics-supply-chain 2026-06-16T16:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilink-opens-gmp-enzyme-manufacturing-facility-ships-first-commercial-batch-to-streamline-rna-therapeutics-supply-chain 2026-06-16T16:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-warns-ace-inhibitor-induced-angioedema-may-be-bradykinin-mediated-and-unresponsive-to-standard-anaphylaxis-treatment 2026-06-16T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-warns-ace-inhibitor-induced-angioedema-may-be-bradykinin-mediated-and-unresponsive-to-standard-anaphylaxis-treatment 2026-06-16T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/rethinking-natural-product-discovery-bridging-ethnopharmacology-and-complex-systems-science 2026-06-16T15:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rethinking-natural-product-discovery-bridging-ethnopharmacology-and-complex-systems-science 2026-06-16T15:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-protillion-biosciences-ink-510-million-ai-driven-biologics-discovery-partnership 2026-06-16T15:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-protillion-biosciences-ink-510-million-ai-driven-biologics-discovery-partnership 2026-06-16T15:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/qc-healthcare-launches-as-diversified-healthtech-holding-company-with-ambitions-across-telehealth-ai-clinical-research-and-population-health 2026-06-16T15:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qc-healthcare-launches-as-diversified-healthtech-holding-company-with-ambitions-across-telehealth-ai-clinical-research-and-population-health 2026-06-16T15:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/pleopharma-doses-first-patient-in-pivotal-phase-3-trial-of-pp-01-for-cannabis-withdrawal-presents-phase-2-data-showing-43-reduction-in-irritability 2026-06-16T15:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pleopharma-doses-first-patient-in-pivotal-phase-3-trial-of-pp-01-for-cannabis-withdrawal-presents-phase-2-data-showing-43-reduction-in-irritability 2026-06-16T15:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-telehealth-from-compounding-boom-to-regulatory-reckoning-and-the-rise-of-turnkey-platforms 2026-06-16T15:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-telehealth-from-compounding-boom-to-regulatory-reckoning-and-the-rise-of-turnkey-platforms 2026-06-16T15:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/oligonucleotide-therapeutics-from-scientific-concept-to-a-clinically-validated-drug-modality 2026-06-16T15:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oligonucleotide-therapeutics-from-scientific-concept-to-a-clinically-validated-drug-modality 2026-06-16T15:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/impli-secures-ps1-4m-nihr-grant-to-advance-continuous-hormone-monitoring-patch-for-ivf-clinical-validation 2026-06-16T15:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impli-secures-ps1-4m-nihr-grant-to-advance-continuous-hormone-monitoring-patch-for-ivf-clinical-validation 2026-06-16T15:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/splisense-secures-up-to-13-million-from-cystic-fibrosis-foundation-to-advance-phase-2b-study-of-inhaled-aso-therapy-spl84 2026-06-16T15:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splisense-secures-up-to-13-million-from-cystic-fibrosis-foundation-to-advance-phase-2b-study-of-inhaled-aso-therapy-spl84 2026-06-16T15:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/ctad-and-addf-join-forces-to-launch-biotech-showcase-at-ctad-2026-aiming-to-accelerate-next-generation-alzheimer-s-therapies 2026-06-16T15:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctad-and-addf-join-forces-to-launch-biotech-showcase-at-ctad-2026-aiming-to-accelerate-next-generation-alzheimer-s-therapies 2026-06-16T15:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-bioeconomy-surges-to-195-billion-targets-300-billion-by-2030-with-biopharma-innovation-push 2026-06-16T15:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-bioeconomy-surges-to-195-billion-targets-300-billion-by-2030-with-biopharma-innovation-push 2026-06-16T15:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/programmable-mrna-3utr-engineering-restores-mhc-i-and-overcomes-immune-evasion-in-prostate-cancer 2026-06-16T15:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/programmable-mrna-3utr-engineering-restores-mhc-i-and-overcomes-immune-evasion-in-prostate-cancer 2026-06-16T15:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/the-evolving-role-of-biotechnology-keynote-speakers-in-shaping-pharmaceutical-r-d-strategy 2026-06-16T15:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-evolving-role-of-biotechnology-keynote-speakers-in-shaping-pharmaceutical-r-d-strategy 2026-06-16T15:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/ai-meets-biotech-germany-s-next-innovation-wave-in-drug-discovery-and-digital-health 2026-06-16T15:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-meets-biotech-germany-s-next-innovation-wave-in-drug-discovery-and-digital-health 2026-06-16T15:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-skinvive-by-juvederm-as-first-hyaluronic-acid-injectable-for-horizontal-neck-lines 2026-06-16T15:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-skinvive-by-juvederm-as-first-hyaluronic-acid-injectable-for-horizontal-neck-lines 2026-06-16T15:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/gorrie-family-makes-10-million-transformative-investment-in-alzheimer-s-disease-research-at-uab 2026-06-16T13:43:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gorrie-family-makes-10-million-transformative-investment-in-alzheimer-s-disease-research-at-uab 2026-06-16T13:43:17+00:00 hourly 0.9 https://trial.medpath.com/news/matica-bio-and-cirsium-biosciences-forge-open-access-partnership-to-transform-aav-gene-therapy-manufacturing 2026-06-16T13:42:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matica-bio-and-cirsium-biosciences-forge-open-access-partnership-to-transform-aav-gene-therapy-manufacturing 2026-06-16T13:42:46+00:00 hourly 0.9 https://trial.medpath.com/news/hormonal-cycles-may-determine-how-intranasal-brain-drugs-reach-their-target-study-finds 2026-06-16T13:42:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hormonal-cycles-may-determine-how-intranasal-brain-drugs-reach-their-target-study-finds 2026-06-16T13:42:34+00:00 hourly 0.9 https://trial.medpath.com/news/sex-disparities-in-oncology-clinical-trials-moving-beyond-counting-women-toward-true-equity 2026-06-16T13:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sex-disparities-in-oncology-clinical-trials-moving-beyond-counting-women-toward-true-equity 2026-06-16T13:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/zobio-launches-integrated-dna-encoded-library-hit-discovery-service-for-challenging-drug-targets 2026-06-16T13:42:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zobio-launches-integrated-dna-encoded-library-hit-discovery-service-for-challenging-drug-targets 2026-06-16T13:42:32+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-tissuecypher-test-surpasses-100000-orders-advancing-precision-risk-assessment-for-barrett-s-esophagus 2026-06-16T13:42:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-tissuecypher-test-surpasses-100000-orders-advancing-precision-risk-assessment-for-barrett-s-esophagus 2026-06-16T13:42:32+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-restructures-leadership-appoints-new-cco-ahead-of-up-to-three-product-launches-in-2027-2028 2026-06-16T13:42:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-restructures-leadership-appoints-new-cco-ahead-of-up-to-three-product-launches-in-2027-2028 2026-06-16T13:42:30+00:00 hourly 0.9 https://trial.medpath.com/news/who-issues-global-alerts-on-falsified-oncology-drugs-jakavi-and-darzalex-found-across-five-countries 2026-06-16T13:42:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-issues-global-alerts-on-falsified-oncology-drugs-jakavi-and-darzalex-found-across-five-countries 2026-06-16T13:42:10+00:00 hourly 0.9 https://trial.medpath.com/news/endodna-launches-bios-an-adaptive-clinical-decision-support-platform-that-turns-genetic-data-into-living-intelligence-for-precision-medicine 2026-06-16T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endodna-launches-bios-an-adaptive-clinical-decision-support-platform-that-turns-genetic-data-into-living-intelligence-for-precision-medicine 2026-06-16T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/ai-chatbot-risk-in-mental-health-new-simulation-framework-quantifies-harm-potential-across-models 2026-06-16T13:42:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-chatbot-risk-in-mental-health-new-simulation-framework-quantifies-harm-potential-across-models 2026-06-16T13:42:03+00:00 hourly 0.9 https://trial.medpath.com/news/orchid-pharma-enters-russia-licensing-pact-for-novel-antibiotic-exblifep-us-deal-in-advanced-talks 2026-06-16T13:41:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchid-pharma-enters-russia-licensing-pact-for-novel-antibiotic-exblifep-us-deal-in-advanced-talks 2026-06-16T13:41:51+00:00 hourly 0.9 https://trial.medpath.com/news/italy-charts-european-strategy-for-rare-diseases-with-rome-charter-as-monitorare-report-reveals-progress-and-persistent-regional-gaps 2026-06-16T13:41:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italy-charts-european-strategy-for-rare-diseases-with-rome-charter-as-monitorare-report-reveals-progress-and-persistent-regional-gaps 2026-06-16T13:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/claret-capital-partners-commits-eur43m-to-inventiva-s-eur130m-financing-for-pivotal-mash-phase-3-trial 2026-06-16T13:41:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/claret-capital-partners-commits-eur43m-to-inventiva-s-eur130m-financing-for-pivotal-mash-phase-3-trial 2026-06-16T13:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/christchurch-medtech-zuuka-seeks-2m-for-wearable-drug-delivery-platform-targeting-us-launch 2026-06-16T13:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/christchurch-medtech-zuuka-seeks-2m-for-wearable-drug-delivery-platform-targeting-us-launch 2026-06-16T13:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/west-launches-synchronytm-prefillable-syringe-system-to-support-biologics-and-vaccines-in-asia-pacific-markets 2026-06-16T13:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/west-launches-synchronytm-prefillable-syringe-system-to-support-biologics-and-vaccines-in-asia-pacific-markets 2026-06-16T13:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-technology-advances-project-phoenix-into-nationwide-ai-driven-virtual-data-collection-for-veterans-exposed-to-burn-pit-toxins 2026-06-16T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-medical-technology-advances-project-phoenix-into-nationwide-ai-driven-virtual-data-collection-for-veterans-exposed-to-burn-pit-toxins 2026-06-16T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/osteosarcoma-pipeline-2026-hs-20093-leads-phase-iii-as-over-25-companies-advance-novel-therapies 2026-06-16T11:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osteosarcoma-pipeline-2026-hs-20093-leads-phase-iii-as-over-25-companies-advance-novel-therapies 2026-06-16T11:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/marea-therapeutics-presents-phase-1-data-for-mar002-a-first-in-class-ghr-antibody-showing-up-to-64-igf-1-suppression-in-acromegaly-at-endo-2026 2026-06-16T11:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marea-therapeutics-presents-phase-1-data-for-mar002-a-first-in-class-ghr-antibody-showing-up-to-64-igf-1-suppression-in-acromegaly-at-endo-2026 2026-06-16T11:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-cybersecurity-enters-a-constant-disruption-era-as-major-breaches-hit-medical-device-and-distribution-giants 2026-06-16T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-cybersecurity-enters-a-constant-disruption-era-as-major-breaches-hit-medical-device-and-distribution-giants 2026-06-16T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-grants-exclusive-license-to-antharis-therapeutics-for-dual-payload-adc-development-in-gastrointestinal-cancers 2026-06-16T10:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-grants-exclusive-license-to-antharis-therapeutics-for-dual-payload-adc-development-in-gastrointestinal-cancers 2026-06-16T10:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/two-pronged-nudge-strategy-significantly-increases-serious-illness-conversations-in-cancer-care 2026-06-16T10:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-pronged-nudge-strategy-significantly-increases-serious-illness-conversations-in-cancer-care 2026-06-16T10:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-trial-reports-preliminary-cognitive-improvement-in-early-dementia-using-personalised-approach 2026-06-16T10:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-trial-reports-preliminary-cognitive-improvement-in-early-dementia-using-personalised-approach 2026-06-16T10:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-diagnostics-market-projected-to-reach-30-74-billion-by-2030-driven-by-precision-medicine-and-early-disease-detection 2026-06-16T10:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-diagnostics-market-projected-to-reach-30-74-billion-by-2030-driven-by-precision-medicine-and-early-disease-detection 2026-06-16T10:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/lung-transplant-recipient-reaches-6961-meter-summit-without-supplemental-oxygen-setting-new-altitude-record 2026-06-16T10:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-transplant-recipient-reaches-6961-meter-summit-without-supplemental-oxygen-setting-new-altitude-record 2026-06-16T10:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-class-ii-recall-of-duloxetine-over-nitrosamine-impurity-risk 2026-06-16T10:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-class-ii-recall-of-duloxetine-over-nitrosamine-impurity-risk 2026-06-16T10:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-engineer-tissue-resident-nk-cells-that-infiltrate-and-slow-solid-tumors-in-mice 2026-06-16T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-engineer-tissue-resident-nk-cells-that-infiltrate-and-slow-solid-tumors-in-mice 2026-06-16T10:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbial-metabolites-may-shape-vulnerability-to-stress-related-mental-disorders-review-finds 2026-06-16T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbial-metabolites-may-shape-vulnerability-to-stress-related-mental-disorders-review-finds 2026-06-16T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aplagon-raises-eur4-8m-to-expand-apac-antithrombotic-therapy-into-phase-ii-trial-for-avf-maturation-failure 2026-06-16T08:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aplagon-raises-eur4-8m-to-expand-apac-antithrombotic-therapy-into-phase-ii-trial-for-avf-maturation-failure 2026-06-16T08:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/istesso-begins-phase-ii-trial-of-leramistat-for-sarcopenia-in-rheumatoid-arthritis-patients 2026-06-16T08:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/istesso-begins-phase-ii-trial-of-leramistat-for-sarcopenia-in-rheumatoid-arthritis-patients 2026-06-16T08:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/hospital-hvac-systems-market-to-reach-usd-22-44-billion-by-2034-driven-by-infection-control-and-smart-ventilation-demand 2026-06-16T07:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hospital-hvac-systems-market-to-reach-usd-22-44-billion-by-2034-driven-by-infection-control-and-smart-ventilation-demand 2026-06-16T07:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/cj-bio-america-agrees-to-90000-settlement-for-lizard-creek-spill-that-killed-72000-fish 2026-06-16T07:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cj-bio-america-agrees-to-90000-settlement-for-lizard-creek-spill-that-killed-72000-fish 2026-06-16T07:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/italy-s-pharmaceutical-formulary-revision-threatens-price-cuts-of-up-to-40-for-off-patent-medicines 2026-06-16T07:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italy-s-pharmaceutical-formulary-revision-threatens-price-cuts-of-up-to-40-for-off-patent-medicines 2026-06-16T07:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/neuroscientific-biopharmaceuticals-locks-in-fda-pre-ind-meeting-for-stemsmart-in-refractory-crohn-s-disease 2026-06-16T07:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroscientific-biopharmaceuticals-locks-in-fda-pre-ind-meeting-for-stemsmart-in-refractory-crohn-s-disease 2026-06-16T07:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/alithea-genomics-launches-mercurius-1536-drug-seq-for-ultra-high-throughput-transcriptomic-screening 2026-06-16T06:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alithea-genomics-launches-mercurius-1536-drug-seq-for-ultra-high-throughput-transcriptomic-screening 2026-06-16T06:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/stroke-is-the-third-leading-cause-of-death-for-women-yet-they-remain-underrepresented-in-clinical-trials 2026-06-16T05:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stroke-is-the-third-leading-cause-of-death-for-women-yet-they-remain-underrepresented-in-clinical-trials 2026-06-16T05:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-launches-industry-s-smallest-sterile-1-5-ml-rtu-cartridge-for-glp-1-insulin-and-hormone-therapies 2026-06-16T05:07:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schott-pharma-launches-industry-s-smallest-sterile-1-5-ml-rtu-cartridge-for-glp-1-insulin-and-hormone-therapies 2026-06-16T05:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-wins-china-nmpa-approval-for-world-s-first-fast-dissolving-albumin-bound-paclitaxel-in-metastatic-breast-cancer 2026-06-16T05:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-wins-china-nmpa-approval-for-world-s-first-fast-dissolving-albumin-bound-paclitaxel-in-metastatic-breast-cancer 2026-06-16T05:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/automated-glioblastoma-organoid-platform-reveals-vulnerability-to-proteasome-and-hdac-inhibitors 2026-06-16T05:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-glioblastoma-organoid-platform-reveals-vulnerability-to-proteasome-and-hdac-inhibitors 2026-06-16T05:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/first-comprehensive-map-of-b-cell-diversification-during-malaria-reveals-spleen-as-alternative-site-for-b-cell-production 2026-06-16T05:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-comprehensive-map-of-b-cell-diversification-during-malaria-reveals-spleen-as-alternative-site-for-b-cell-production 2026-06-16T05:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/pioneering-hiv-researcher-at-cu-anschutz-drives-development-of-long-acting-therapies-eyes-once-a-year-injectable 2026-06-16T04:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneering-hiv-researcher-at-cu-anschutz-drives-development-of-long-acting-therapies-eyes-once-a-year-injectable 2026-06-16T04:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/fourth-ever-human-case-of-rare-tick-borne-rickettsia-lanei-confirmed-in-northern-california 2026-06-16T04:07:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fourth-ever-human-case-of-rare-tick-borne-rickettsia-lanei-confirmed-in-northern-california 2026-06-16T04:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/lifestyle-intervention-outperforms-metformin-in-reducing-long-term-multimorbidity-risk-landmark-nih-study-finds 2026-06-16T04:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifestyle-intervention-outperforms-metformin-in-reducing-long-term-multimorbidity-risk-landmark-nih-study-finds 2026-06-16T04:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/herceptin-biosimilars-market-to-reach-usd-10-4-billion-by-2036-as-trastuzumab-biosimilars-dominate-demand 2026-06-16T04:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herceptin-biosimilars-market-to-reach-usd-10-4-billion-by-2036-as-trastuzumab-biosimilars-dominate-demand 2026-06-16T04:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/single-amino-acid-switch-determines-coronavirus-spillover-from-bats-to-humans 2026-06-16T02:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-amino-acid-switch-determines-coronavirus-spillover-from-bats-to-humans 2026-06-16T02:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-oral-systemic-connection-how-gum-disease-links-to-cardiovascular-cognitive-and-metabolic-health 2026-06-16T02:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-oral-systemic-connection-how-gum-disease-links-to-cardiovascular-cognitive-and-metabolic-health 2026-06-16T02:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-launches-140-million-annual-research-funding-initiative-with-two-major-grant-programs 2026-06-16T01:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-launches-140-million-annual-research-funding-initiative-with-two-major-grant-programs 2026-06-16T01:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/the-late-stage-premium-how-big-pharma-s-patent-cliff-is-reshaping-global-biotech-deal-dynamics 2026-06-16T00:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-late-stage-premium-how-big-pharma-s-patent-cliff-is-reshaping-global-biotech-deal-dynamics 2026-06-16T00:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/floyd-county-medical-center-sets-october-1-groundbreaking-for-39-5-million-phase-ii-expansion 2026-06-16T00:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/floyd-county-medical-center-sets-october-1-groundbreaking-for-39-5-million-phase-ii-expansion 2026-06-16T00:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-plans-separation-of-immune-medicine-platform-eyes-strategic-options-for-drug-discovery-business 2026-06-16T00:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-plans-separation-of-immune-medicine-platform-eyes-strategic-options-for-drug-discovery-business 2026-06-16T00:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-proposes-cy-2027-updates-to-esrd-prospective-payment-system-and-quality-incentive-program 2026-06-15T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-proposes-cy-2027-updates-to-esrd-prospective-payment-system-and-quality-incentive-program 2026-06-15T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/pennington-biomedical-launches-clinical-trial-of-cagrisema-a-dual-glp-1-amylin-weight-loss-drug-aiming-to-reduce-side-effects 2026-06-15T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pennington-biomedical-launches-clinical-trial-of-cagrisema-a-dual-glp-1-amylin-weight-loss-drug-aiming-to-reduce-side-effects 2026-06-15T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/dronabinol-shows-promise-for-ptsd-related-nightmares-in-randomized-controlled-trial 2026-06-15T23:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dronabinol-shows-promise-for-ptsd-related-nightmares-in-randomized-controlled-trial 2026-06-15T23:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/otulin-mutation-identified-as-cause-of-pediatric-onset-pyoderma-gangrenosum-tnf-blockade-shows-therapeutic-promise 2026-06-15T23:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otulin-mutation-identified-as-cause-of-pediatric-onset-pyoderma-gangrenosum-tnf-blockade-shows-therapeutic-promise 2026-06-15T23:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotechnology-becomes-a-measure-of-national-power-as-u-s-reframes-research-as-a-security-objective 2026-06-15T23:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotechnology-becomes-a-measure-of-national-power-as-u-s-reframes-research-as-a-security-objective 2026-06-15T23:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/plant-based-fats-linked-to-improved-long-term-survival-in-prostate-cancer-patients 2026-06-15T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plant-based-fats-linked-to-improved-long-term-survival-in-prostate-cancer-patients 2026-06-15T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/slas-europe-2026-draws-record-1500-delegates-as-lab-automation-and-ai-driven-drug-discovery-take-center-stage 2026-06-15T22:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/slas-europe-2026-draws-record-1500-delegates-as-lab-automation-and-ai-driven-drug-discovery-take-center-stage 2026-06-15T22:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/va-community-care-vascular-surgery-costs-surge-as-pad-referrals-nearly-triple-over-five-years 2026-06-15T22:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/va-community-care-vascular-surgery-costs-surge-as-pad-referrals-nearly-triple-over-five-years 2026-06-15T22:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/aha-and-asco-joint-statement-calls-for-redefining-cardiovascular-endpoints-in-oncology-trials 2026-06-15T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aha-and-asco-joint-statement-calls-for-redefining-cardiovascular-endpoints-in-oncology-trials 2026-06-15T22:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/cuba-s-healthcare-system-in-crisis-cancer-survival-rates-drop-as-energy-blockade-disrupts-critical-care 2026-06-15T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuba-s-healthcare-system-in-crisis-cancer-survival-rates-drop-as-energy-blockade-disrupts-critical-care 2026-06-15T21:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/gold-pathway-cuts-diabetes-emergencies-in-older-cancer-patients-on-steroid-therapy 2026-06-15T20:46:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gold-pathway-cuts-diabetes-emergencies-in-older-cancer-patients-on-steroid-therapy 2026-06-15T20:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/checkpoint-inhibitor-refractory-cancer-market-poised-for-growth-as-novel-immuno-oncology-candidates-target-resistance 2026-06-15T20:46:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/checkpoint-inhibitor-refractory-cancer-market-poised-for-growth-as-novel-immuno-oncology-candidates-target-resistance 2026-06-15T20:46:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-clarifying-orange-book-patent-information-submission-for-nda-holders 2026-06-15T20:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-clarifying-orange-book-patent-information-submission-for-nda-holders 2026-06-15T20:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/neuroprotection-in-glaucoma-from-memantine-s-failure-to-nicotinamide-s-promise 2026-06-15T20:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroprotection-in-glaucoma-from-memantine-s-failure-to-nicotinamide-s-promise 2026-06-15T20:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-secures-landmark-victory-in-u-s-patent-infringement-case-against-amgen-jury-awards-20-2-million 2026-06-15T20:45:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-secures-landmark-victory-in-u-s-patent-infringement-case-against-amgen-jury-awards-20-2-million 2026-06-15T20:45:38+00:00 hourly 0.9 https://trial.medpath.com/news/global-mental-disorder-cases-reach-1-17-billion-as-youth-diagnoses-and-treatment-gaps-widen 2026-06-15T20:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-mental-disorder-cases-reach-1-17-billion-as-youth-diagnoses-and-treatment-gaps-widen 2026-06-15T20:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-announces-1-billion-investment-in-jacksonville-vision-operations 2026-06-15T20:02:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-announces-1-billion-investment-in-jacksonville-vision-operations 2026-06-15T20:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/agentic-ai-reshapes-healthcare-operations-from-scheduling-to-drug-discovery-autonomous-systems-demonstrate-measurable-roi 2026-06-15T20:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agentic-ai-reshapes-healthcare-operations-from-scheduling-to-drug-discovery-autonomous-systems-demonstrate-measurable-roi 2026-06-15T20:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/hillhurst-bio-doses-first-subject-in-phase-2a-trial-of-hbi-002-an-oral-carbon-monoxide-based-therapy-for-parkinson-s-disease 2026-06-15T20:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillhurst-bio-doses-first-subject-in-phase-2a-trial-of-hbi-002-an-oral-carbon-monoxide-based-therapy-for-parkinson-s-disease 2026-06-15T20:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/nano-dimension-to-merge-with-infinite-epigenetics-creating-ai-powered-preventive-health-and-diagnostics-company 2026-06-15T20:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nano-dimension-to-merge-with-infinite-epigenetics-creating-ai-powered-preventive-health-and-diagnostics-company 2026-06-15T20:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-background-shapes-cancer-evolution-trajectories-landmark-mouse-study-reveals 2026-06-15T20:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-background-shapes-cancer-evolution-trajectories-landmark-mouse-study-reveals 2026-06-15T20:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/cgrp-targeted-therapies-reshape-migraine-care-unanswered-questions-on-non-response-safety-and-personalization 2026-06-15T20:00:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgrp-targeted-therapies-reshape-migraine-care-unanswered-questions-on-non-response-safety-and-personalization 2026-06-15T20:00:23+00:00 hourly 0.9 https://trial.medpath.com/news/lsu-researchers-receive-409592-nih-grant-to-uncover-brain-mechanisms-driving-opioid-relapse 2026-06-15T20:00:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lsu-researchers-receive-409592-nih-grant-to-uncover-brain-mechanisms-driving-opioid-relapse 2026-06-15T20:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/study-of-5-8-billion-medicines-dispensed-in-england-exposes-stark-health-inequalities 2026-06-15T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-of-5-8-billion-medicines-dispensed-in-england-exposes-stark-health-inequalities 2026-06-15T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/janelia-research-campus-launches-decade-long-initiative-to-decode-the-vertebrate-brain-using-ai-and-a-transparent-fish 2026-06-15T18:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janelia-research-campus-launches-decade-long-initiative-to-decode-the-vertebrate-brain-using-ai-and-a-transparent-fish 2026-06-15T18:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/calcium-and-vitamin-d-supplements-show-little-to-no-benefit-for-fracture-and-fall-prevention-major-bmj-review-finds 2026-06-15T18:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcium-and-vitamin-d-supplements-show-little-to-no-benefit-for-fracture-and-fall-prevention-major-bmj-review-finds 2026-06-15T18:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/worldwide-healthstaff-solutions-places-320-internationally-trained-dialysis-nurses-across-49-states-amid-persistent-workforce-shortages 2026-06-15T18:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/worldwide-healthstaff-solutions-places-320-internationally-trained-dialysis-nurses-across-49-states-amid-persistent-workforce-shortages 2026-06-15T18:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-and-ibm-forum-highlights-quantum-computing-advances-for-drug-discovery-and-undruggable-targets 2026-06-15T18:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-and-ibm-forum-highlights-quantum-computing-advances-for-drug-discovery-and-undruggable-targets 2026-06-15T18:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/blood-proteins-reveal-which-aging-cells-may-raise-disease-risk-landmark-study-shows 2026-06-15T18:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-proteins-reveal-which-aging-cells-may-raise-disease-risk-landmark-study-shows 2026-06-15T18:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/egfr-inhibitors-market-poised-for-7-9-cagr-growth-through-2036-driven-by-next-generation-tkis-adcs-and-bispecific-antibodies 2026-06-15T18:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egfr-inhibitors-market-poised-for-7-9-cagr-growth-through-2036-driven-by-next-generation-tkis-adcs-and-bispecific-antibodies 2026-06-15T18:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/hearing-aid-use-associated-with-23-lower-dementia-risk-in-adults-with-epilepsy-and-hearing-loss 2026-06-15T17:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hearing-aid-use-associated-with-23-lower-dementia-risk-in-adults-with-epilepsy-and-hearing-loss 2026-06-15T17:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/interferon-g-drives-neutrophil-pd-l1-expression-limiting-cancer-immunotherapy-efficacy 2026-06-15T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/interferon-g-drives-neutrophil-pd-l1-expression-limiting-cancer-immunotherapy-efficacy 2026-06-15T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-halts-navacaprant-development-after-three-phase-iii-failures-in-major-depressive-disorder-cuts-35-of-workforce 2026-06-15T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-halts-navacaprant-development-after-three-phase-iii-failures-in-major-depressive-disorder-cuts-35-of-workforce 2026-06-15T17:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/american-heart-association-launches-primary-care-perspectives-platform-to-improve-early-heart-failure-risk-detection 2026-06-15T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-heart-association-launches-primary-care-perspectives-platform-to-improve-early-heart-failure-risk-detection 2026-06-15T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/tulisokibart-meets-primary-and-key-secondary-endpoints-in-phase-3-atlas-uc-trial-for-ulcerative-colitis 2026-06-15T17:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tulisokibart-meets-primary-and-key-secondary-endpoints-in-phase-3-atlas-uc-trial-for-ulcerative-colitis 2026-06-15T17:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/radical-numerics-launches-with-50m-seed-round-to-build-general-biological-intelligence-for-drug-discovery-and-biodefense 2026-06-15T17:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radical-numerics-launches-with-50m-seed-round-to-build-general-biological-intelligence-for-drug-discovery-and-biodefense 2026-06-15T17:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/wayne-state-researcher-earns-3-1m-nih-grant-to-improve-her2-breast-cancer-treatment 2026-06-15T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wayne-state-researcher-earns-3-1m-nih-grant-to-improve-her2-breast-cancer-treatment 2026-06-15T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-brain-health-secures-50-million-series-b-financing-and-european-partnership-with-medice-for-precision-psychiatry-pipeline 2026-06-15T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmnc-brain-health-secures-50-million-series-b-financing-and-european-partnership-with-medice-for-precision-psychiatry-pipeline 2026-06-15T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-obagi-saypha-chiq-injectable-hyaluronic-acid-gel-for-cheek-augmentation 2026-06-15T17:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-obagi-saypha-chiq-injectable-hyaluronic-acid-gel-for-cheek-augmentation 2026-06-15T17:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/senate-bill-seeks-to-link-fda-and-uspto-disclosures-raising-concerns-over-patent-integrity-and-innovation 2026-06-15T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-bill-seeks-to-link-fda-and-uspto-disclosures-raising-concerns-over-patent-integrity-and-innovation 2026-06-15T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/china-nexus-espionage-group-unc6508-targeted-north-american-medical-research-networks-in-multiyear-cyber-campaign 2026-06-15T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nexus-espionage-group-unc6508-targeted-north-american-medical-research-networks-in-multiyear-cyber-campaign 2026-06-15T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-proposes-rule-to-close-evergreening-loophole-targeting-subcutaneous-keytruda-and-opdivo-for-price-negotiation 2026-06-15T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-proposes-rule-to-close-evergreening-loophole-targeting-subcutaneous-keytruda-and-opdivo-for-price-negotiation 2026-06-15T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-fewer-diabetic-foot-ulcers-but-higher-charcot-risk-than-dpp-4-inhibitors 2026-06-15T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-fewer-diabetic-foot-ulcers-but-higher-charcot-risk-than-dpp-4-inhibitors 2026-06-15T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ipss-m-identifies-hidden-high-risk-biology-in-clinically-lower-risk-mds-guiding-earlier-transplant-decisions 2026-06-15T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipss-m-identifies-hidden-high-risk-biology-in-clinically-lower-risk-mds-guiding-earlier-transplant-decisions 2026-06-15T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-appoints-former-terns-cfo-andrew-gengos-as-chief-financial-officer-amid-pivotal-phase-3-pancreatic-cancer-program 2026-06-15T16:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-appoints-former-terns-cfo-andrew-gengos-as-chief-financial-officer-amid-pivotal-phase-3-pancreatic-cancer-program 2026-06-15T16:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-launches-fesiltytm-fibrinogen-concentrate-in-the-u-s-for-congenital-fibrinogen-deficiency 2026-06-15T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-launches-fesiltytm-fibrinogen-concentrate-in-the-u-s-for-congenital-fibrinogen-deficiency 2026-06-15T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/laser-phase-plate-breakthrough-extends-cryo-em-to-smaller-proteins-opening-new-frontiers-in-structural-biology 2026-06-15T16:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laser-phase-plate-breakthrough-extends-cryo-em-to-smaller-proteins-opening-new-frontiers-in-structural-biology 2026-06-15T16:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/the-science-to-story-gap-why-56-of-drug-launches-miss-expectations-and-how-emerging-biotechs-can-close-it 2026-06-15T16:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-science-to-story-gap-why-56-of-drug-launches-miss-expectations-and-how-emerging-biotechs-can-close-it 2026-06-15T16:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-receives-neural-stem-cell-therapy-in-pioneering-huntington-s-disease-trial-at-uci-health 2026-06-15T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-receives-neural-stem-cell-therapy-in-pioneering-huntington-s-disease-trial-at-uci-health 2026-06-15T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/huntington-s-disease-market-poised-for-14-cagr-growth-through-2036-as-disease-modifying-therapies-advance 2026-06-15T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huntington-s-disease-market-poised-for-14-cagr-growth-through-2036-as-disease-modifying-therapies-advance 2026-06-15T16:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/covid-vaccination-linked-to-24-reduction-in-all-cause-cardiac-events-in-million-veteran-study 2026-06-15T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-vaccination-linked-to-24-reduction-in-all-cause-cardiac-events-in-million-veteran-study 2026-06-15T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/gelita-launches-ultra-low-endotoxin-medellapro-gelatin-for-sensitive-biomedical-applications 2026-06-15T16:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gelita-launches-ultra-low-endotoxin-medellapro-gelatin-for-sensitive-biomedical-applications 2026-06-15T16:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/unproven-stem-cell-treatments-for-autism-surge-in-the-us-amid-regulatory-rollback-under-rfk-jr 2026-06-15T15:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unproven-stem-cell-treatments-for-autism-surge-in-the-us-amid-regulatory-rollback-under-rfk-jr 2026-06-15T15:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/artificial-intelligence-improves-diagnostic-accuracy-in-clinical-breast-pathology-a-comprehensive-review 2026-06-15T15:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artificial-intelligence-improves-diagnostic-accuracy-in-clinical-breast-pathology-a-comprehensive-review 2026-06-15T15:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-tonmya-becomes-first-new-fibromyalgia-drug-in-over-15-years-transforming-the-chronic-pain-treatment-landscape 2026-06-15T15:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-tonmya-becomes-first-new-fibromyalgia-drug-in-over-15-years-transforming-the-chronic-pain-treatment-landscape 2026-06-15T15:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/arialys-therapeutics-doses-first-anre-patient-with-precision-therapy-art5803-as-fda-clears-u-s-phase-2-trial 2026-06-15T15:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arialys-therapeutics-doses-first-anre-patient-with-precision-therapy-art5803-as-fda-clears-u-s-phase-2-trial 2026-06-15T15:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/multidisciplinary-coordination-and-emerging-biomarkers-transform-care-for-high-risk-cutaneous-squamous-cell-carcinoma 2026-06-15T15:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multidisciplinary-coordination-and-emerging-biomarkers-transform-care-for-high-risk-cutaneous-squamous-cell-carcinoma 2026-06-15T15:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/klick-labs-and-mayo-clinic-launch-vocal-biomarker-collaboration-for-chronic-disease-detection 2026-06-15T15:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/klick-labs-and-mayo-clinic-launch-vocal-biomarker-collaboration-for-chronic-disease-detection 2026-06-15T15:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/maagi-medical-s-i-series-multimodal-tumor-therapy-debuts-at-apscvir-2026-showcasing-8-month-os-improvement-in-pancreatic-cancer 2026-06-15T15:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maagi-medical-s-i-series-multimodal-tumor-therapy-debuts-at-apscvir-2026-showcasing-8-month-os-improvement-in-pancreatic-cancer 2026-06-15T15:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/chemists-achieve-breakthrough-in-molecular-editing-alkyl-swap-method-transforms-drug-discovery 2026-06-15T15:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemists-achieve-breakthrough-in-molecular-editing-alkyl-swap-method-transforms-drug-discovery 2026-06-15T15:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/scientist-com-to-host-expert-webinar-on-new-approach-methodologies-for-drug-discovery-and-development 2026-06-15T15:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientist-com-to-host-expert-webinar-on-new-approach-methodologies-for-drug-discovery-and-development 2026-06-15T15:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/bjorn-gysell-and-family-donate-sek-80-million-to-karolinska-institutet-for-ai-driven-prostate-cancer-research 2026-06-15T15:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bjorn-gysell-and-family-donate-sek-80-million-to-karolinska-institutet-for-ai-driven-prostate-cancer-research 2026-06-15T15:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/ccrm-omniabio-and-avectas-partner-to-evaluate-next-generation-automated-cell-therapy-manufacturing-platform 2026-06-15T15:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ccrm-omniabio-and-avectas-partner-to-evaluate-next-generation-automated-cell-therapy-manufacturing-platform 2026-06-15T15:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/fondazione-telethon-appoints-graciana-diez-roux-as-new-scientific-director 2026-06-15T14:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fondazione-telethon-appoints-graciana-diez-roux-as-new-scientific-director 2026-06-15T14:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-and-biomap-launch-megastream-techbio-to-build-ai-native-complex-biologics-platform 2026-06-15T14:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-and-biomap-launch-megastream-techbio-to-build-ai-native-complex-biologics-platform 2026-06-15T14:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-secures-abu-dhabi-ind-clearance-for-neo212-advancing-global-glioblastoma-strategy 2026-06-15T14:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-secures-abu-dhabi-ind-clearance-for-neo212-advancing-global-glioblastoma-strategy 2026-06-15T14:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/beekeeper-s-naturals-recalls-saline-nasal-spray-over-aspergillus-contamination-risk 2026-06-15T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beekeeper-s-naturals-recalls-saline-nasal-spray-over-aspergillus-contamination-risk 2026-06-15T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-ebola-vaccine-that-sat-on-the-shelf-for-15-years-why-a-promising-bundibugyo-candidate-is-only-now-racing-toward-human-trials 2026-06-15T13:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-ebola-vaccine-that-sat-on-the-shelf-for-15-years-why-a-promising-bundibugyo-candidate-is-only-now-racing-toward-human-trials 2026-06-15T13:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/light-controlled-molecular-switch-wakes-dormant-lung-cancer-cells-to-restore-treatment-vulnerability 2026-06-15T13:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-controlled-molecular-switch-wakes-dormant-lung-cancer-cells-to-restore-treatment-vulnerability 2026-06-15T13:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/ena-respiratory-secures-key-u-s-patent-allowances-for-tlr2-agonist-inna-051-strengthening-copd-exacerbation-franchise 2026-06-15T13:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ena-respiratory-secures-key-u-s-patent-allowances-for-tlr2-agonist-inna-051-strengthening-copd-exacerbation-franchise 2026-06-15T13:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-aav-fgf21-gene-therapy-extends-health-span-by-20-54-in-aged-mice 2026-06-15T13:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-aav-fgf21-gene-therapy-extends-health-span-by-20-54-in-aged-mice 2026-06-15T13:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/atom-therapeutics-advances-lingdolinurad-into-china-phase-3-trial-for-gout-reports-strong-phase-2b-efficacy-data 2026-06-15T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atom-therapeutics-advances-lingdolinurad-into-china-phase-3-trial-for-gout-reports-strong-phase-2b-efficacy-data 2026-06-15T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/redefining-obesity-success-boehringer-ingelheim-s-push-beyond-the-scale-toward-comprehensive-metabolic-health 2026-06-15T13:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redefining-obesity-success-boehringer-ingelheim-s-push-beyond-the-scale-toward-comprehensive-metabolic-health 2026-06-15T13:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/patient-voices-are-redefining-rare-disease-innovation-say-biotech-leaders 2026-06-15T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-voices-are-redefining-rare-disease-innovation-say-biotech-leaders 2026-06-15T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/q1-2025-therapeutics-earnings-novavax-moderna-lead-surprises-as-precision-medicine-tailwinds-shape-sector 2026-06-15T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/q1-2025-therapeutics-earnings-novavax-moderna-lead-surprises-as-precision-medicine-tailwinds-shape-sector 2026-06-15T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/first-patients-worldwide-access-affordable-generic-cystic-fibrosis-treatment-triko-priced-96-below-vertex-s-trikafta 2026-06-15T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patients-worldwide-access-affordable-generic-cystic-fibrosis-treatment-triko-priced-96-below-vertex-s-trikafta 2026-06-15T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-deep-brain-stimulation-synchronized-to-gait-phase-improves-walking-and-reduces-falls-in-parkinson-s-disease 2026-06-15T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-deep-brain-stimulation-synchronized-to-gait-phase-improves-walking-and-reduces-falls-in-parkinson-s-disease 2026-06-15T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/deep-learning-models-decode-common-and-rare-noncoding-variant-effects-across-cellular-and-developmental-contexts 2026-06-15T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deep-learning-models-decode-common-and-rare-noncoding-variant-effects-across-cellular-and-developmental-contexts 2026-06-15T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/difficult-to-treat-immune-mediated-inflammatory-diseases-demand-holistic-strategy-beyond-drug-switching 2026-06-15T10:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/difficult-to-treat-immune-mediated-inflammatory-diseases-demand-holistic-strategy-beyond-drug-switching 2026-06-15T10:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/four-asbmb-members-named-2025-national-academy-of-inventors-fellows 2026-06-15T09:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-asbmb-members-named-2025-national-academy-of-inventors-fellows 2026-06-15T09:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/bio-usawa-appoints-former-pfizer-chief-medical-officer-dr-aida-habtezion-to-board-of-directors 2026-06-15T09:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-usawa-appoints-former-pfizer-chief-medical-officer-dr-aida-habtezion-to-board-of-directors 2026-06-15T09:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-satri-cel-first-ever-car-t-therapy-for-solid-tumors-marks-historic-milestone-in-gastric-cancer 2026-06-15T09:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-satri-cel-first-ever-car-t-therapy-for-solid-tumors-marks-historic-milestone-in-gastric-cancer 2026-06-15T09:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/female-tbi-patients-26-less-likely-to-be-admitted-to-specialized-trauma-centres-ontario-study-finds 2026-06-15T08:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/female-tbi-patients-26-less-likely-to-be-admitted-to-specialized-trauma-centres-ontario-study-finds 2026-06-15T08:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/pelago-bioscience-acquires-rg-discovery-to-create-integrated-drug-discovery-cro-spanning-biology-and-chemistry 2026-06-15T08:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelago-bioscience-acquires-rg-discovery-to-create-integrated-drug-discovery-cro-spanning-biology-and-chemistry 2026-06-15T08:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/flinders-honours-professor-huji-xu-for-pioneering-world-first-allogeneic-car-t-cell-therapy-for-autoimmune-diseases 2026-06-15T08:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flinders-honours-professor-huji-xu-for-pioneering-world-first-allogeneic-car-t-cell-therapy-for-autoimmune-diseases 2026-06-15T08:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/4basebio-appoints-mrna-pioneer-dr-jeff-coller-to-strategic-advisory-board 2026-06-15T08:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4basebio-appoints-mrna-pioneer-dr-jeff-coller-to-strategic-advisory-board 2026-06-15T08:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-ambelvist-r-gadoquatrane-receives-fda-approval-as-lowest-dose-macrocyclic-gadolinium-based-contrast-agent-for-mri 2026-06-15T08:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-ambelvist-r-gadoquatrane-receives-fda-approval-as-lowest-dose-macrocyclic-gadolinium-based-contrast-agent-for-mri 2026-06-15T08:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/fas-investigates-teva-and-grotex-for-alleged-unfair-competition-over-generic-apixaban-launch 2026-06-15T06:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fas-investigates-teva-and-grotex-for-alleged-unfair-competition-over-generic-apixaban-launch 2026-06-15T06:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-expands-qiacuity-digital-pcr-ecosystem-with-new-gene-expression-assays-high-multiplex-capabilities-and-workflow-automation 2026-06-15T06:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-expands-qiacuity-digital-pcr-ecosystem-with-new-gene-expression-assays-high-multiplex-capabilities-and-workflow-automation 2026-06-15T06:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-mrna-based-cancer-vaccine-for-lynch-syndrome-as-part-of-post-pandemic-portfolio-diversification 2026-06-15T06:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-mrna-based-cancer-vaccine-for-lynch-syndrome-as-part-of-post-pandemic-portfolio-diversification 2026-06-15T06:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letters-to-seafood-firms-over-botulism-controls-and-import-violations 2026-06-15T06:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letters-to-seafood-firms-over-botulism-controls-and-import-violations 2026-06-15T06:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/t-curx-secures-swissmedic-approval-for-first-in-human-trial-of-non-viral-car-t-therapy-tcx-001 2026-06-15T06:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-curx-secures-swissmedic-approval-for-first-in-human-trial-of-non-viral-car-t-therapy-tcx-001 2026-06-15T06:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/brain-organoids-reveal-why-alzheimer-s-patients-respond-differently-to-common-antidepressants 2026-06-15T04:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-organoids-reveal-why-alzheimer-s-patients-respond-differently-to-common-antidepressants 2026-06-15T04:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-first-to-market-generic-bosutinib-in-the-us-securing-180-day-exclusivity 2026-06-15T04:39:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-launches-first-to-market-generic-bosutinib-in-the-us-securing-180-day-exclusivity 2026-06-15T04:39:31+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-s-immunomic-therapeutics-receives-pmda-approval-for-phase-1-trial-of-sarna-vaccine-iti-9001-for-japanese-cedar-pollen-allergy 2026-06-15T03:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-s-immunomic-therapeutics-receives-pmda-approval-for-phase-1-trial-of-sarna-vaccine-iti-9001-for-japanese-cedar-pollen-allergy 2026-06-15T03:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-chamber-urges-removal-of-novelty-test-to-ease-listing-rules-for-biotech-and-innovative-companies 2026-06-15T01:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-chamber-urges-removal-of-novelty-test-to-ease-listing-rules-for-biotech-and-innovative-companies 2026-06-15T01:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-insider-sale-reflects-routine-options-exercise-not-a-red-flag-for-investors 2026-06-15T00:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-insider-sale-reflects-routine-options-exercise-not-a-red-flag-for-investors 2026-06-15T00:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-new-medicines-drive-11-pharma-growth-as-biosimilar-erosion-stabilizes-in-europe 2026-06-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-new-medicines-drive-11-pharma-growth-as-biosimilar-erosion-stabilizes-in-europe 2026-06-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/testosterone-therapy-in-men-may-be-overprescribed-study-finds-only-12-of-prescriptions-follow-clinical-guidelines 2026-06-14T22:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/testosterone-therapy-in-men-may-be-overprescribed-study-finds-only-12-of-prescriptions-follow-clinical-guidelines 2026-06-14T22:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/trialify-a-patient-inspired-app-simplifies-clinical-trial-matching-for-cancer-patients 2026-06-14T22:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trialify-a-patient-inspired-app-simplifies-clinical-trial-matching-for-cancer-patients 2026-06-14T22:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/menopausal-hormone-therapy-associated-with-69-reduced-odds-of-low-bone-mineral-density-in-postmenopausal-women 2026-06-14T22:07:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menopausal-hormone-therapy-associated-with-69-reduced-odds-of-low-bone-mineral-density-in-postmenopausal-women 2026-06-14T22:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/victoria-installs-biontech-biontainer-units-positioning-melbourne-as-a-global-mrna-manufacturing-hub 2026-06-14T22:07:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/victoria-installs-biontech-biontainer-units-positioning-melbourne-as-a-global-mrna-manufacturing-hub 2026-06-14T22:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/egypt-s-vaccine-city-to-attract-240-million-in-investments-by-2030-positioning-country-as-regional-biotech-hub 2026-06-14T21:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egypt-s-vaccine-city-to-attract-240-million-in-investments-by-2030-positioning-country-as-regional-biotech-hub 2026-06-14T21:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/dietary-beverages-and-ginger-may-support-blood-pressure-management-dietitians-say 2026-06-14T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dietary-beverages-and-ginger-may-support-blood-pressure-management-dietitians-say 2026-06-14T20:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-and-blood-biomarker-studies-advance-toward-first-in-life-diagnosis-of-chronic-traumatic-encephalopathy 2026-06-14T20:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pet-imaging-and-blood-biomarker-studies-advance-toward-first-in-life-diagnosis-of-chronic-traumatic-encephalopathy 2026-06-14T20:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/reversing-prediabetes-cuts-cardiovascular-death-and-heart-failure-risk-by-58-landmark-analysis-reveals 2026-06-14T19:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reversing-prediabetes-cuts-cardiovascular-death-and-heart-failure-risk-by-58-landmark-analysis-reveals 2026-06-14T19:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/silver-nanoparticles-enable-5-fold-boost-in-dna-assembly-efficiency-japanese-researchers-report 2026-06-14T19:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silver-nanoparticles-enable-5-fold-boost-in-dna-assembly-efficiency-japanese-researchers-report 2026-06-14T19:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/gbma-intervenes-in-landmark-australian-high-court-case-on-pharmaceutical-patent-term-extensions 2026-06-14T19:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gbma-intervenes-in-landmark-australian-high-court-case-on-pharmaceutical-patent-term-extensions 2026-06-14T19:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/central-and-peripheral-glutamatergic-biomarkers-delineate-three-distinct-phenotypes-in-olanzapine-treated-schizophrenia 2026-06-14T18:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/central-and-peripheral-glutamatergic-biomarkers-delineate-three-distinct-phenotypes-in-olanzapine-treated-schizophrenia 2026-06-14T18:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/oman-s-ministry-of-health-launches-nationwide-campaign-to-combat-counterfeit-medical-products 2026-06-14T18:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oman-s-ministry-of-health-launches-nationwide-campaign-to-combat-counterfeit-medical-products 2026-06-14T18:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/grappa-trial-atlg-superior-to-post-transplant-cyclophosphamide-for-gvhd-prophylaxis-in-unrelated-donor-stem-cell-transplants 2026-06-14T17:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grappa-trial-atlg-superior-to-post-transplant-cyclophosphamide-for-gvhd-prophylaxis-in-unrelated-donor-stem-cell-transplants 2026-06-14T17:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/urogen-pharma-cmo-mark-schoenberg-sells-400000-in-stock-following-191-share-surge 2026-06-14T17:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urogen-pharma-cmo-mark-schoenberg-sells-400000-in-stock-following-191-share-surge 2026-06-14T17:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/ntu-led-study-identifies-stool-biomarker-angptl4-as-early-indicator-of-gut-barrier-dysfunction-in-fatty-liver-disease 2026-06-14T16:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ntu-led-study-identifies-stool-biomarker-angptl4-as-early-indicator-of-gut-barrier-dysfunction-in-fatty-liver-disease 2026-06-14T16:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/copley-acquisition-and-ignite-proteomics-strike-150m-spac-deal-to-bring-precision-oncology-proteomics-platform-to-public-markets 2026-06-14T16:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/copley-acquisition-and-ignite-proteomics-strike-150m-spac-deal-to-bring-precision-oncology-proteomics-platform-to-public-markets 2026-06-14T16:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-pharmaceuticals-director-sells-2501-shares-in-pre-planned-option-exercise-what-the-royalty-driven-biotech-model-means-for-investors 2026-06-14T16:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligand-pharmaceuticals-director-sells-2501-shares-in-pre-planned-option-exercise-what-the-royalty-driven-biotech-model-means-for-investors 2026-06-14T16:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/ebola-treatment-centers-open-at-outbreak-epicenter-in-drc-s-ituri-province 2026-06-14T16:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebola-treatment-centers-open-at-outbreak-epicenter-in-drc-s-ituri-province 2026-06-14T16:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/aurinia-launches-preserve-phase-4-trial-lupkynis-combined-with-biologics-to-pursue-faster-complete-renal-response-in-lupus-nephritis 2026-06-14T14:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurinia-launches-preserve-phase-4-trial-lupkynis-combined-with-biologics-to-pursue-faster-complete-renal-response-in-lupus-nephritis 2026-06-14T14:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-elevated-rates-of-hypotensive-events-in-patients-on-antihypertensives 2026-06-14T14:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-elevated-rates-of-hypotensive-events-in-patients-on-antihypertensives 2026-06-14T14:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/celldex-s-bispecific-cdx-622-shows-rapid-mast-cell-depletion-and-favorable-safety-in-first-in-human-phase-1-trial 2026-06-14T12:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celldex-s-bispecific-cdx-622-shows-rapid-mast-cell-depletion-and-favorable-safety-in-first-in-human-phase-1-trial 2026-06-14T12:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-gal-syndrome-fda-approves-first-drug-for-life-threatening-tick-borne-meat-allergy-affecting-450000-americans 2026-06-14T12:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-gal-syndrome-fda-approves-first-drug-for-life-threatening-tick-borne-meat-allergy-affecting-450000-americans 2026-06-14T12:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-bevacizumab-shows-benefit-in-selected-child-pugh-b-hcc-patients-albex-score-identifies-best-candidates 2026-06-14T11:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-bevacizumab-shows-benefit-in-selected-child-pugh-b-hcc-patients-albex-score-identifies-best-candidates 2026-06-14T11:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-hears-centre-s-refusal-to-fund-treatment-for-child-with-lrba-deficiency-under-india-s-rare-disease-policy 2026-06-14T11:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-hears-centre-s-refusal-to-fund-treatment-for-child-with-lrba-deficiency-under-india-s-rare-disease-policy 2026-06-14T11:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-mri-predicts-chronic-kidney-disease-risk-before-nephrectomy-pilot-study-shows 2026-06-14T11:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-mri-predicts-chronic-kidney-disease-risk-before-nephrectomy-pilot-study-shows 2026-06-14T11:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-india-ltd-hits-all-time-high-before-10-71-weekly-correction-amid-profit-taking 2026-06-14T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-india-ltd-hits-all-time-high-before-10-71-weekly-correction-amid-profit-taking 2026-06-14T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/cortical-labs-launches-world-s-first-commercial-biological-computer-ushering-in-synthetic-intelligence 2026-06-14T10:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cortical-labs-launches-world-s-first-commercial-biological-computer-ushering-in-synthetic-intelligence 2026-06-14T10:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/patient-matched-transcriptomics-validate-in-vitro-colonic-epithelium-models-for-ibd-research 2026-06-14T10:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-matched-transcriptomics-validate-in-vitro-colonic-epithelium-models-for-ibd-research 2026-06-14T10:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapy-and-immunotherapy-transform-outcomes-in-late-stage-cancers-diagnosed-through-unusual-ocular-symptoms 2026-06-14T09:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-therapy-and-immunotherapy-transform-outcomes-in-late-stage-cancers-diagnosed-through-unusual-ocular-symptoms 2026-06-14T09:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/mit-researchers-develop-wearable-ultrasound-patch-that-could-replace-surgical-pacemakers 2026-06-14T09:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-researchers-develop-wearable-ultrasound-patch-that-could-replace-surgical-pacemakers 2026-06-14T09:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-investigates-second-infant-botulism-outbreak-linked-to-organic-powdered-formula-in-seven-months 2026-06-14T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-investigates-second-infant-botulism-outbreak-linked-to-organic-powdered-formula-in-seven-months 2026-06-14T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/nice-issues-final-guidance-on-sotatercept-for-pulmonary-arterial-hypertension-expanding-treatment-options 2026-06-14T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-issues-final-guidance-on-sotatercept-for-pulmonary-arterial-hypertension-expanding-treatment-options 2026-06-14T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/complete-sucrose-removal-from-low-fat-diet-disrupts-gut-microbiome-and-metabolic-health-in-mouse-study 2026-06-14T03:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complete-sucrose-removal-from-low-fat-diet-disrupts-gut-microbiome-and-metabolic-health-in-mouse-study 2026-06-14T03:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/forest-therapy-gains-scientific-ground-as-evidence-based-mental-health-intervention 2026-06-14T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forest-therapy-gains-scientific-ground-as-evidence-based-mental-health-intervention 2026-06-14T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bio-techne-a-high-quality-life-sciences-picks-and-shovels-play-amid-cyclical-headwinds 2026-06-14T02:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-techne-a-high-quality-life-sciences-picks-and-shovels-play-amid-cyclical-headwinds 2026-06-14T02:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/kerala-nipah-response-monoclonal-antibody-therapy-deployed-as-contact-list-expands-to-100 2026-06-14T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kerala-nipah-response-monoclonal-antibody-therapy-deployed-as-contact-list-expands-to-100 2026-06-14T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/san-diego-s-curebound-cancer-challenge-returns-as-grant-applications-surge-21-signaling-urgent-need-for-early-stage-cancer-research-funding 2026-06-13T23:58:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/san-diego-s-curebound-cancer-challenge-returns-as-grant-applications-surge-21-signaling-urgent-need-for-early-stage-cancer-research-funding 2026-06-13T23:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/precision-fermentation-engineering-next-generation-microbial-platforms-for-sustainable-biomanufacturing 2026-06-13T23:58:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-fermentation-engineering-next-generation-microbial-platforms-for-sustainable-biomanufacturing 2026-06-13T23:58:18+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-launches-two-phase-2-trials-of-denikitug-in-her2-negative-gi-cancers-and-mss-colorectal-cancer 2026-06-13T23:58:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-launches-two-phase-2-trials-of-denikitug-in-her2-negative-gi-cancers-and-mss-colorectal-cancer 2026-06-13T23:58:17+00:00 hourly 0.9 https://trial.medpath.com/news/cencora-and-kite-forge-distribution-partnership-to-expand-u-s-access-to-car-t-cell-therapies-yescarta-and-tecartus 2026-06-13T23:58:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cencora-and-kite-forge-distribution-partnership-to-expand-u-s-access-to-car-t-cell-therapies-yescarta-and-tecartus 2026-06-13T23:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/longtime-wabc-tv-anchor-bill-ritter-steps-down-following-early-stage-alzheimer-s-diagnosis 2026-06-13T22:04:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longtime-wabc-tv-anchor-bill-ritter-steps-down-following-early-stage-alzheimer-s-diagnosis 2026-06-13T22:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/women-s-thyroid-cancer-risk-may-be-linked-to-reproductive-lifespan-and-hormone-therapy 2026-06-13T22:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/women-s-thyroid-cancer-risk-may-be-linked-to-reproductive-lifespan-and-hormone-therapy 2026-06-13T22:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/ukctocs-secondary-analysis-reveals-ovarian-cancer-screening-failure-driven-by-ultra-short-early-detection-window-not-test-sensitivity 2026-06-13T22:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ukctocs-secondary-analysis-reveals-ovarian-cancer-screening-failure-driven-by-ultra-short-early-detection-window-not-test-sensitivity 2026-06-13T22:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/gaza-food-security-gains-at-risk-as-aid-declines-and-humanitarian-crisis-deepens-ipc-warns 2026-06-13T22:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gaza-food-security-gains-at-risk-as-aid-declines-and-humanitarian-crisis-deepens-ipc-warns 2026-06-13T22:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/retraction-watch-science-investigation-exposes-tsunami-of-misleading-medical-studies-driven-by-trinetx-research-tool 2026-06-13T22:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retraction-watch-science-investigation-exposes-tsunami-of-misleading-medical-studies-driven-by-trinetx-research-tool 2026-06-13T22:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-microscopy-reveals-hidden-drug-effects-through-nucleolus-shape-changes 2026-06-13T22:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-microscopy-reveals-hidden-drug-effects-through-nucleolus-shape-changes 2026-06-13T22:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/the-new-face-of-lung-cancer-why-experts-say-it-s-time-to-rethink-who-s-at-risk 2026-06-13T20:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-new-face-of-lung-cancer-why-experts-say-it-s-time-to-rethink-who-s-at-risk 2026-06-13T20:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-pharmaceuticals-a-deep-dive-into-the-leadership-and-commercial-infrastructure-behind-a-biopharma-powerhouse 2026-06-13T20:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-pharmaceuticals-a-deep-dive-into-the-leadership-and-commercial-infrastructure-behind-a-biopharma-powerhouse 2026-06-13T20:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-chp-investigates-two-clusters-of-carbapenemase-producing-enterobacteriaceae-carriers-in-elderly-care-homes 2026-06-13T20:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-chp-investigates-two-clusters-of-carbapenemase-producing-enterobacteriaceae-carriers-in-elderly-care-homes 2026-06-13T20:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/veeva-systems-selected-by-ucb-to-deploy-safety-suite-across-global-pharmacovigilance-operations 2026-06-13T20:07:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veeva-systems-selected-by-ucb-to-deploy-safety-suite-across-global-pharmacovigilance-operations 2026-06-13T20:07:53+00:00 hourly 0.9 https://trial.medpath.com/news/most-cancer-patients-prefer-learning-their-diagnosis-from-a-clinician-not-the-portal 2026-06-13T19:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/most-cancer-patients-prefer-learning-their-diagnosis-from-a-clinician-not-the-portal 2026-06-13T19:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/breaking-the-wet-lab-bottleneck-in-ai-driven-antibody-discovery 2026-06-13T19:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breaking-the-wet-lab-bottleneck-in-ai-driven-antibody-discovery 2026-06-13T19:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/luspatercept-demonstrates-durable-transfusion-independence-in-lower-risk-mds-across-two-pivotal-trials 2026-06-13T18:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luspatercept-demonstrates-durable-transfusion-independence-in-lower-risk-mds-across-two-pivotal-trials 2026-06-13T18:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-launches-ngs-partner-enablement-program-and-oem-collaborations-at-eshg-2026-to-accelerate-clinical-genomics-adoption 2026-06-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgi-tech-launches-ngs-partner-enablement-program-and-oem-collaborations-at-eshg-2026-to-accelerate-clinical-genomics-adoption 2026-06-13T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-pediatric-rhabdomyosarcoma-therapeutics-fgfr4-myod1-and-novel-degrader-strategies-take-center-stage 2026-06-13T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-pediatric-rhabdomyosarcoma-therapeutics-fgfr4-myod1-and-novel-degrader-strategies-take-center-stage 2026-06-13T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/rare-okur-chung-neurodevelopmental-syndrome-diagnosed-in-singapore-toddler-via-whole-exome-sequencing 2026-06-13T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-okur-chung-neurodevelopmental-syndrome-diagnosed-in-singapore-toddler-via-whole-exome-sequencing 2026-06-13T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/kos-biotechnology-partners-closes-123-million-inaugural-life-sciences-fund-marking-greece-s-largest-vc-launch 2026-06-13T17:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kos-biotechnology-partners-closes-123-million-inaugural-life-sciences-fund-marking-greece-s-largest-vc-launch 2026-06-13T17:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/carrie-ann-inaba-partners-with-novartis-on-sjout-campaign-to-raise-sjogren-s-disease-awareness 2026-06-13T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carrie-ann-inaba-partners-with-novartis-on-sjout-campaign-to-raise-sjogren-s-disease-awareness 2026-06-13T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-officially-recognizes-chagas-disease-as-endemic-in-the-united-states-with-an-estimated-300000-americans-affected 2026-06-13T16:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-officially-recognizes-chagas-disease-as-endemic-in-the-united-states-with-an-estimated-300000-americans-affected 2026-06-13T16:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/erectile-dysfunction-as-a-sentinel-marker-why-the-penis-is-a-barometer-of-men-s-cardiovascular-and-metabolic-health 2026-06-13T16:07:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erectile-dysfunction-as-a-sentinel-marker-why-the-penis-is-a-barometer-of-men-s-cardiovascular-and-metabolic-health 2026-06-13T16:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/td-cowen-maintains-hold-rating-on-novartis-sets-180-price-target 2026-06-13T16:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/td-cowen-maintains-hold-rating-on-novartis-sets-180-price-target 2026-06-13T16:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-first-to-market-generic-bosutinib-400mg-in-the-u-s-challenging-pfizer-s-bosulif 2026-06-13T15:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-launches-first-to-market-generic-bosutinib-400mg-in-the-u-s-challenging-pfizer-s-bosulif 2026-06-13T15:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-urge-caution-over-large-scale-newborn-genome-screening-citing-overdiagnosis-risks 2026-06-13T12:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-urge-caution-over-large-scale-newborn-genome-screening-citing-overdiagnosis-risks 2026-06-13T12:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/global-immunoassay-market-projected-to-reach-us-55-9-billion-by-2034-growing-at-5-2-cagr 2026-06-13T10:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-immunoassay-market-projected-to-reach-us-55-9-billion-by-2034-growing-at-5-2-cagr 2026-06-13T10:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/10-year-partner-2-outcomes-confirm-tavr-durability-matches-surgery-in-intermediate-risk-aortic-stenosis 2026-06-13T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10-year-partner-2-outcomes-confirm-tavr-durability-matches-surgery-in-intermediate-risk-aortic-stenosis 2026-06-13T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/cd99l2-identified-as-novel-disease-gene-for-spastic-ataxia-and-hereditary-spastic-paraplegia 2026-06-13T09:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd99l2-identified-as-novel-disease-gene-for-spastic-ataxia-and-hereditary-spastic-paraplegia 2026-06-13T09:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/invesco-biotechnology-genome-etf-pbe-declares-0-8106-dividend-marking-significant-payout-increase 2026-06-13T08:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invesco-biotechnology-genome-etf-pbe-declares-0-8106-dividend-marking-significant-payout-increase 2026-06-13T08:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/hinge-health-co-founder-and-major-backer-shed-shares-amid-101-stock-surge 2026-06-13T08:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hinge-health-co-founder-and-major-backer-shed-shares-amid-101-stock-surge 2026-06-13T08:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/biological-age-tests-show-promise-for-disease-prevention-but-experts-urge-caution-on-consumer-interpretation 2026-06-13T07:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biological-age-tests-show-promise-for-disease-prevention-but-experts-urge-caution-on-consumer-interpretation 2026-06-13T07:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-dexcom-stelo-as-first-over-the-counter-continuous-glucose-monitor-for-children-aged-2-and-older 2026-06-13T06:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-dexcom-stelo-as-first-over-the-counter-continuous-glucose-monitor-for-children-aged-2-and-older 2026-06-13T06:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/microsoft-discovery-platform-launches-general-availability-bringing-agentic-ai-to-scientific-r-d 2026-06-13T05:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microsoft-discovery-platform-launches-general-availability-bringing-agentic-ai-to-scientific-r-d 2026-06-13T05:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/deion-sanders-declares-he-is-cancer-free-after-aggressive-bladder-cancer-battle-credits-early-detection 2026-06-13T05:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deion-sanders-declares-he-is-cancer-free-after-aggressive-bladder-cancer-battle-credits-early-detection 2026-06-13T05:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/phosphatidylcholine-decline-emerges-as-a-malleable-driver-of-mitochondrial-aging 2026-06-13T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phosphatidylcholine-decline-emerges-as-a-malleable-driver-of-mitochondrial-aging 2026-06-13T05:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/cms-issues-first-proposed-rule-to-make-medicare-drug-price-negotiation-program-permanent 2026-06-13T03:06:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-issues-first-proposed-rule-to-make-medicare-drug-price-negotiation-program-permanent 2026-06-13T03:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/traws-pharma-defers-phase-2a-influenza-challenge-trial-after-mhra-negative-review-fda-hold-remains-on-bird-flu-development 2026-06-13T02:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/traws-pharma-defers-phase-2a-influenza-challenge-trial-after-mhra-negative-review-fda-hold-remains-on-bird-flu-development 2026-06-13T02:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/risk-stratified-monitoring-framework-for-glaucoma-suspects-could-safely-reduce-low-risk-follow-up-visits 2026-06-13T01:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risk-stratified-monitoring-framework-for-glaucoma-suspects-could-safely-reduce-low-risk-follow-up-visits 2026-06-13T01:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-cfdna-demonstrates-95-sensitivity-for-detecting-hpv-driven-oropharyngeal-cancer-and-predicts-recurrence-months-before-imaging 2026-06-13T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpv-cfdna-demonstrates-95-sensitivity-for-detecting-hpv-driven-oropharyngeal-cancer-and-predicts-recurrence-months-before-imaging 2026-06-13T01:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/antibody-profiles-offer-insights-into-long-covid-cognitive-symptoms-study-finds 2026-06-13T00:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antibody-profiles-offer-insights-into-long-covid-cognitive-symptoms-study-finds 2026-06-13T00:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/antibody-therapeutics-market-to-reach-us-737-6-billion-by-2034-driven-by-oncology-and-precision-medicine 2026-06-13T00:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antibody-therapeutics-market-to-reach-us-737-6-billion-by-2034-driven-by-oncology-and-precision-medicine 2026-06-13T00:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-tat-asia-2026-highlights-ai-driven-drug-development-theranostics-and-gastric-cancer-advances-in-hong-kong 2026-06-12T22:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-tat-asia-2026-highlights-ai-driven-drug-development-theranostics-and-gastric-cancer-advances-in-hong-kong 2026-06-12T22:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/ayvakit-avapritinib-emerges-as-targeted-therapy-for-indolent-systemic-mastocytosis-addressing-root-cause-of-rare-mast-cell-disease 2026-06-12T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ayvakit-avapritinib-emerges-as-targeted-therapy-for-indolent-systemic-mastocytosis-addressing-root-cause-of-rare-mast-cell-disease 2026-06-12T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposed-rule-lets-drugmakers-skirt-medicare-price-negotiations-undermining-seniors-savings 2026-06-12T22:41:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposed-rule-lets-drugmakers-skirt-medicare-price-negotiations-undermining-seniors-savings 2026-06-12T22:41:13+00:00 hourly 0.9 https://trial.medpath.com/news/arizona-treatment-center-pioneers-glp-1-peptide-use-in-addiction-recovery 2026-06-12T22:40:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arizona-treatment-center-pioneers-glp-1-peptide-use-in-addiction-recovery 2026-06-12T22:40:54+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-discloses-clinical-trial-data-breach-affecting-pseudonymized-patient-information 2026-06-12T22:40:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-discloses-clinical-trial-data-breach-affecting-pseudonymized-patient-information 2026-06-12T22:40:13+00:00 hourly 0.9 https://trial.medpath.com/news/scripps-research-fentanyl-vaccine-blocks-overdoses-by-targeting-entire-drug-class 2026-06-12T22:39:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scripps-research-fentanyl-vaccine-blocks-overdoses-by-targeting-entire-drug-class 2026-06-12T22:39:57+00:00 hourly 0.9 https://trial.medpath.com/news/lyticgen-files-patent-for-crispr-engineered-bacteriophage-vdx-10-targeting-mrsa 2026-06-12T21:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyticgen-files-patent-for-crispr-engineered-bacteriophage-vdx-10-targeting-mrsa 2026-06-12T21:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/intracare-rebrands-clinical-research-division-as-careon-expanding-trial-access-across-texas 2026-06-12T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intracare-rebrands-clinical-research-division-as-careon-expanding-trial-access-across-texas 2026-06-12T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-billing-tools-drive-healthcare-costs-to-17-year-high-pwc-report-finds 2026-06-12T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-billing-tools-drive-healthcare-costs-to-17-year-high-pwc-report-finds 2026-06-12T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/prac-finds-inconsistent-evidence-on-paternal-valproate-neurodevelopmental-risk-maintains-precautionary-measures 2026-06-12T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prac-finds-inconsistent-evidence-on-paternal-valproate-neurodevelopmental-risk-maintains-precautionary-measures 2026-06-12T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/brc-therapeutics-appoints-veteran-pharma-executive-ron-eastman-to-board-of-directors 2026-06-12T21:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brc-therapeutics-appoints-veteran-pharma-executive-ron-eastman-to-board-of-directors 2026-06-12T21:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-kidney-injury-warning-for-otc-weight-loss-pill-alli-orlistat 2026-06-12T20:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-kidney-injury-warning-for-otc-weight-loss-pill-alli-orlistat 2026-06-12T20:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/montana-state-researchers-discover-backup-cellular-pathway-for-cysteine-production-opening-new-avenues-for-cancer-therapy 2026-06-12T20:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montana-state-researchers-discover-backup-cellular-pathway-for-cysteine-production-opening-new-avenues-for-cancer-therapy 2026-06-12T20:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/abbisko-teams-up-with-eli-lilly-in-up-to-1-9-billion-oncology-drug-discovery-collaboration 2026-06-12T19:40:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbisko-teams-up-with-eli-lilly-in-up-to-1-9-billion-oncology-drug-discovery-collaboration 2026-06-12T19:40:39+00:00 hourly 0.9 https://trial.medpath.com/news/nature-medicine-benchmark-study-finds-general-purpose-llms-outperform-fda-cleared-clinical-ai-tools-across-all-medical-question-types 2026-06-12T19:40:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nature-medicine-benchmark-study-finds-general-purpose-llms-outperform-fda-cleared-clinical-ai-tools-across-all-medical-question-types 2026-06-12T19:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/yap1-emerges-as-key-driver-of-small-cell-lung-cancer-relapse-and-therapy-resistance 2026-06-12T19:40:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yap1-emerges-as-key-driver-of-small-cell-lung-cancer-relapse-and-therapy-resistance 2026-06-12T19:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-innovates-2026-day-two-over-40-startups-secure-investor-commitments-254-5-million-in-funding-announced 2026-06-12T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-innovates-2026-day-two-over-40-startups-secure-investor-commitments-254-5-million-in-funding-announced 2026-06-12T18:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/uva-joins-spark-global-to-accelerate-translation-of-academic-discoveries-into-new-medicines 2026-06-12T17:39:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-joins-spark-global-to-accelerate-translation-of-academic-discoveries-into-new-medicines 2026-06-12T17:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/purminds-files-fiscal-q2-2026-financials-advances-pcaob-audit-toward-otcqb-qx-uplisting 2026-06-12T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purminds-files-fiscal-q2-2026-financials-advances-pcaob-audit-toward-otcqb-qx-uplisting 2026-06-12T17:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/protext-mobility-unveils-corporate-platform-and-venezuela-loi-signaling-biotech-pharma-digital-infrastructure-ambitions 2026-06-12T17:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protext-mobility-unveils-corporate-platform-and-venezuela-loi-signaling-biotech-pharma-digital-infrastructure-ambitions 2026-06-12T17:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/europe-s-biotech-act-a-regulatory-blueprint-to-close-the-innovation-gap-and-anchor-biomanufacturing-in-the-eu 2026-06-12T17:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/europe-s-biotech-act-a-regulatory-blueprint-to-close-the-innovation-gap-and-anchor-biomanufacturing-in-the-eu 2026-06-12T17:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/rapport-therapeutics-fully-prepared-to-launch-novel-epilepsy-drug-rap-219-solo-ceo-says 2026-06-12T17:39:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapport-therapeutics-fully-prepared-to-launch-novel-epilepsy-drug-rap-219-solo-ceo-says 2026-06-12T17:39:04+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-therapeutics-wins-2026-prix-galien-uk-award-for-best-biotechnology-product 2026-06-12T17:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autolus-therapeutics-wins-2026-prix-galien-uk-award-for-best-biotechnology-product 2026-06-12T17:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/merck-streamlines-adc-discovery-with-automated-mass-spectrometry-workflows 2026-06-12T17:37:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-streamlines-adc-discovery-with-automated-mass-spectrometry-workflows 2026-06-12T17:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/synact-s-resomelagon-hits-key-endpoints-in-phase-2b-rheumatoid-arthritis-trial-secures-us-patent-exclusivity-to-2044 2026-06-12T16:09:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synact-s-resomelagon-hits-key-endpoints-in-phase-2b-rheumatoid-arthritis-trial-secures-us-patent-exclusivity-to-2044 2026-06-12T16:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/the-next-decade-of-biotech-cross-border-orchestrators-redefine-global-pharma-innovation 2026-06-12T16:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-next-decade-of-biotech-cross-border-orchestrators-redefine-global-pharma-innovation 2026-06-12T16:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/mit-engineers-develop-gel-coating-for-direct-drug-delivery-to-the-esophagus 2026-06-12T16:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-engineers-develop-gel-coating-for-direct-drug-delivery-to-the-esophagus 2026-06-12T16:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-doses-first-patient-in-phase-iii-mapkeeper-301-trial-of-atebimetinib-plus-modified-gemcitabine-nab-paclitaxel-in-metastatic-pancreatic-cancer 2026-06-12T16:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-doses-first-patient-in-phase-iii-mapkeeper-301-trial-of-atebimetinib-plus-modified-gemcitabine-nab-paclitaxel-in-metastatic-pancreatic-cancer 2026-06-12T16:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/continuous-bioprocessing-market-projected-to-reach-1-64-billion-by-2034-driven-by-biologics-manufacturing-demand 2026-06-12T15:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuous-bioprocessing-market-projected-to-reach-1-64-billion-by-2034-driven-by-biologics-manufacturing-demand 2026-06-12T15:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/jeff-bezos-s-prometheus-raises-12b-to-build-ai-that-could-transform-drug-discovery 2026-06-12T15:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeff-bezos-s-prometheus-raises-12b-to-build-ai-that-could-transform-drug-discovery 2026-06-12T15:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/kfsh-to-showcase-strategic-value-of-tertiary-care-ai-datasets-for-precision-medicine-at-hlth-europe-2026 2026-06-12T15:05:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kfsh-to-showcase-strategic-value-of-tertiary-care-ai-datasets-for-precision-medicine-at-hlth-europe-2026 2026-06-12T15:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/automated-modular-workflow-advances-car-t-manufacturing-for-autoimmune-disease 2026-06-12T15:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-modular-workflow-advances-car-t-manufacturing-for-autoimmune-disease 2026-06-12T15:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-s-national-precision-medicine-strategy-translating-genomic-data-into-asian-healthcare-practice 2026-06-12T14:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-s-national-precision-medicine-strategy-translating-genomic-data-into-asian-healthcare-practice 2026-06-12T14:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/neet-2026-results-over-11-lakh-qualify-as-biotechnology-emerges-as-leading-non-mbbs-healthcare-career-path 2026-06-12T14:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neet-2026-results-over-11-lakh-qualify-as-biotechnology-emerges-as-leading-non-mbbs-healthcare-career-path 2026-06-12T14:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-abandons-cancer-drug-development-in-dramatic-pivot-to-ai-power-infrastructure 2026-06-12T14:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-abandons-cancer-drug-development-in-dramatic-pivot-to-ai-power-infrastructure 2026-06-12T14:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/musc-health-breaks-ground-on-indian-land-medical-center-expanding-cancer-and-specialty-care-across-south-carolina 2026-06-12T14:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/musc-health-breaks-ground-on-indian-land-medical-center-expanding-cancer-and-specialty-care-across-south-carolina 2026-06-12T14:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-drug-pricing-push-exposes-flaws-in-canada-s-health-technology-assessment-system 2026-06-12T14:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-drug-pricing-push-exposes-flaws-in-canada-s-health-technology-assessment-system 2026-06-12T14:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/o-ptir-spectroscopy-advances-submicron-chemical-analysis-for-pharmaceutical-r-d-and-quality-control 2026-06-12T12:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/o-ptir-spectroscopy-advances-submicron-chemical-analysis-for-pharmaceutical-r-d-and-quality-control 2026-06-12T12:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/cizzle-biotechnology-secures-us-patent-for-ciz1b-lung-cancer-biomarker-test 2026-06-12T12:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cizzle-biotechnology-secures-us-patent-for-ciz1b-lung-cancer-biomarker-test 2026-06-12T12:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/malaysian-male-nurses-association-opposes-proposal-to-recruit-15000-indonesian-nurses-amid-workforce-shortage 2026-06-12T12:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaysian-male-nurses-association-opposes-proposal-to-recruit-15000-indonesian-nurses-amid-workforce-shortage 2026-06-12T12:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/no-link-between-cat-ownership-and-asthma-flare-ups-in-children-swedish-registry-study-finds 2026-06-12T11:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/no-link-between-cat-ownership-and-asthma-flare-ups-in-children-swedish-registry-study-finds 2026-06-12T11:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharm-s-tqc2938-becomes-first-st2-antibody-to-show-positive-phase-ii-results-in-allergic-rhinitis 2026-06-12T11:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharm-s-tqc2938-becomes-first-st2-antibody-to-show-positive-phase-ii-results-in-allergic-rhinitis 2026-06-12T11:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/breaking-the-resistance-frontier-integrative-ai-pre-clinical-and-clinical-strategies-for-malaria-eradication 2026-06-12T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breaking-the-resistance-frontier-integrative-ai-pre-clinical-and-clinical-strategies-for-malaria-eradication 2026-06-12T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-dermatological-drugs-market-to-reach-68-9-billion-by-2034-driven-by-biologics-and-precision-therapies 2026-06-12T09:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-dermatological-drugs-market-to-reach-68-9-billion-by-2034-driven-by-biologics-and-precision-therapies 2026-06-12T09:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/soft-tissue-sarcoma-pipeline-gains-momentum-70-companies-advance-75-therapies-across-all-development-stages 2026-06-12T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soft-tissue-sarcoma-pipeline-gains-momentum-70-companies-advance-75-therapies-across-all-development-stages 2026-06-12T08:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/simcere-pharmaceutical-and-stanford-medicine-launch-collaboration-to-develop-first-in-class-therapy-for-idiopathic-pulmonary-fibrosis 2026-06-12T08:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simcere-pharmaceutical-and-stanford-medicine-launch-collaboration-to-develop-first-in-class-therapy-for-idiopathic-pulmonary-fibrosis 2026-06-12T08:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-momelotinib-receives-orphan-drug-designations-in-us-and-eu-for-vexas-syndrome 2026-06-12T08:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-momelotinib-receives-orphan-drug-designations-in-us-and-eu-for-vexas-syndrome 2026-06-12T08:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-gene-therapy-bbm-p002-shows-clean-phase-1-safety-in-parkinson-s-but-regulatory-path-remains-uncharted 2026-06-12T08:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-gene-therapy-bbm-p002-shows-clean-phase-1-safety-in-parkinson-s-but-regulatory-path-remains-uncharted 2026-06-12T08:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/bangladesh-proposes-sweeping-tax-relief-on-pharmaceutical-raw-materials-to-boost-api-self-reliance-and-export-competitiveness 2026-06-12T08:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bangladesh-proposes-sweeping-tax-relief-on-pharmaceutical-raw-materials-to-boost-api-self-reliance-and-export-competitiveness 2026-06-12T08:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-nanozymes-reprogram-the-colorectal-cancer-microenvironment-to-overcome-chemoresistance-and-immune-exclusion 2026-06-12T06:35:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-nanozymes-reprogram-the-colorectal-cancer-microenvironment-to-overcome-chemoresistance-and-immune-exclusion 2026-06-12T06:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-biotech-paradox-world-class-science-yet-a-struggling-startup-ecosystem 2026-06-12T05:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-biotech-paradox-world-class-science-yet-a-struggling-startup-ecosystem 2026-06-12T05:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/base-editing-strategy-rewrites-huntington-s-gene-to-reduce-toxic-fragments-without-silencing-protein-function 2026-06-12T05:40:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/base-editing-strategy-rewrites-huntington-s-gene-to-reduce-toxic-fragments-without-silencing-protein-function 2026-06-12T05:40:13+00:00 hourly 0.9 https://trial.medpath.com/news/crinetics-to-present-long-term-paltusotine-data-and-atumelnant-phase-2-results-at-endo-2026 2026-06-12T05:40:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crinetics-to-present-long-term-paltusotine-data-and-atumelnant-phase-2-results-at-endo-2026 2026-06-12T05:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/il-17ra-drives-copd-progression-by-activating-dual-pyroptosis-pathways-in-alveolar-epithelial-cells 2026-06-12T05:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-17ra-drives-copd-progression-by-activating-dual-pyroptosis-pathways-in-alveolar-epithelial-cells 2026-06-12T05:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-and-spatial-omics-meet-bioengineering-a-new-frontier-in-cancer-diagnosis-and-therapy 2026-06-12T05:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-and-spatial-omics-meet-bioengineering-a-new-frontier-in-cancer-diagnosis-and-therapy 2026-06-12T05:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-expands-full-u-s-commercial-availability-of-tecnis-puresee-edof-iol-for-cataract-surgery 2026-06-12T05:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-expands-full-u-s-commercial-availability-of-tecnis-puresee-edof-iol-for-cataract-surgery 2026-06-12T05:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-phase-2-data-show-transcon-pth-sustains-multi-organ-benefits-in-hypoparathyroidism 2026-06-12T05:38:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-phase-2-data-show-transcon-pth-sustains-multi-organ-benefits-in-hypoparathyroidism 2026-06-12T05:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/peroxisomes-protect-insulin-and-maintain-beta-cell-health-study-finds 2026-06-12T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peroxisomes-protect-insulin-and-maintain-beta-cell-health-study-finds 2026-06-12T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-gumokimab-ak111-an-anti-il-17-monoclonal-antibody-approved-by-china-s-nmpa-for-moderate-to-severe-plaque-psoriasis 2026-06-12T04:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-s-gumokimab-ak111-an-anti-il-17-monoclonal-antibody-approved-by-china-s-nmpa-for-moderate-to-severe-plaque-psoriasis 2026-06-12T04:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/powassan-virus-case-highlights-critical-gaps-in-tick-bite-prevention-and-the-limits-of-standard-doxycycline-prophylaxis 2026-06-12T04:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/powassan-virus-case-highlights-critical-gaps-in-tick-bite-prevention-and-the-limits-of-standard-doxycycline-prophylaxis 2026-06-12T04:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-s-susvimo-as-first-continuous-delivery-therapy-for-diabetic-retinopathy 2026-06-12T04:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-s-susvimo-as-first-continuous-delivery-therapy-for-diabetic-retinopathy 2026-06-12T04:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/three-connecticut-children-die-from-diphenhydramine-overdoses-renewing-fears-over-social-media-benadryl-challenge 2026-06-12T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-connecticut-children-die-from-diphenhydramine-overdoses-renewing-fears-over-social-media-benadryl-challenge 2026-06-12T03:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/vt-ebv-n-shows-95-durable-disease-free-survival-in-ebv-positive-enktl-phase-ii-data-at-eha-2026 2026-06-12T01:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vt-ebv-n-shows-95-durable-disease-free-survival-in-ebv-positive-enktl-phase-ii-data-at-eha-2026 2026-06-12T01:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-announces-successful-early-implantations-of-at-lucia-toric-721p-intraocular-lens-for-cataract-and-astigmatism-correction 2026-06-12T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-announces-successful-early-implantations-of-at-lucia-toric-721p-intraocular-lens-for-cataract-and-astigmatism-correction 2026-06-12T01:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/adma-biologics-faces-securities-class-action-lawsuit-over-alleged-undisclosed-related-party-transactions-and-channel-stuffing 2026-06-12T00:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adma-biologics-faces-securities-class-action-lawsuit-over-alleged-undisclosed-related-party-transactions-and-channel-stuffing 2026-06-12T00:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/penumbra-s-thunderbolt-receives-fda-clearance-as-first-computer-assisted-vacuum-thrombectomy-device-for-acute-ischemic-stroke 2026-06-12T00:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penumbra-s-thunderbolt-receives-fda-clearance-as-first-computer-assisted-vacuum-thrombectomy-device-for-acute-ischemic-stroke 2026-06-12T00:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-rapid-nanopore-sequencing-reshapes-precision-medicine-across-transplantation-infectious-disease-and-oncology 2026-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-rapid-nanopore-sequencing-reshapes-precision-medicine-across-transplantation-infectious-disease-and-oncology 2026-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chroniclebio-appoints-immunology-pioneer-john-mumm-as-cso-to-decode-neuroimmune-disorders-with-multi-omic-precision-platform 2026-06-11T23:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chroniclebio-appoints-immunology-pioneer-john-mumm-as-cso-to-decode-neuroimmune-disorders-with-multi-omic-precision-platform 2026-06-11T23:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/nih-and-bay-area-lyme-foundation-grants-fuel-babesiosis-drug-development-at-university-of-vermont 2026-06-11T23:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-and-bay-area-lyme-foundation-grants-fuel-babesiosis-drug-development-at-university-of-vermont 2026-06-11T23:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-executive-leadership-the-architects-behind-the-kenvue-separation-and-innovative-medicine-growth 2026-06-11T23:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-executive-leadership-the-architects-behind-the-kenvue-separation-and-innovative-medicine-growth 2026-06-11T23:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-reports-109-unregulated-drug-toxicity-deaths-in-may-2026-lowest-monthly-toll-since-february-2020 2026-06-11T22:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/british-columbia-reports-109-unregulated-drug-toxicity-deaths-in-may-2026-lowest-monthly-toll-since-february-2020 2026-06-11T22:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-oklahoma-receives-11-5-million-nih-grant-to-establish-first-of-its-kind-immunoengineering-research-center 2026-06-11T22:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-oklahoma-receives-11-5-million-nih-grant-to-establish-first-of-its-kind-immunoengineering-research-center 2026-06-11T22:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/from-discovery-to-delivery-solving-the-ipsc-cell-therapy-manufacturing-bottleneck 2026-06-11T22:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-discovery-to-delivery-solving-the-ipsc-cell-therapy-manufacturing-bottleneck 2026-06-11T22:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/chepa-regimen-achieves-76-complete-metabolic-response-in-cd30-positive-ptcl-phase-2-trial-results-presented-at-eha-2026 2026-06-11T22:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chepa-regimen-achieves-76-complete-metabolic-response-in-cd30-positive-ptcl-phase-2-trial-results-presented-at-eha-2026 2026-06-11T22:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/data-informed-protocol-optimization-emerges-as-essential-strategy-for-oncology-trial-design 2026-06-11T22:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/data-informed-protocol-optimization-emerges-as-essential-strategy-for-oncology-trial-design 2026-06-11T22:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-faces-decision-on-440-million-palantir-nhs-data-contract-as-break-clause-looms 2026-06-11T21:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-faces-decision-on-440-million-palantir-nhs-data-contract-as-break-clause-looms 2026-06-11T21:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/short-term-postoperative-outcomes-comparable-between-ira-and-ipaa-in-fap-cleveland-clinic-study-finds 2026-06-11T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/short-term-postoperative-outcomes-comparable-between-ira-and-ipaa-in-fap-cleveland-clinic-study-finds 2026-06-11T21:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-gut-microbiome-analysis-reveals-robust-colorectal-cancer-signature-across-27-studies 2026-06-11T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-gut-microbiome-analysis-reveals-robust-colorectal-cancer-signature-across-27-studies 2026-06-11T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-in-three-middle-aged-americans-struggle-with-basic-health-literacy-northwestern-study-finds 2026-06-11T20:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-in-three-middle-aged-americans-struggle-with-basic-health-literacy-northwestern-study-finds 2026-06-11T20:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/the-evolution-of-femtech-from-menstrual-tracking-to-deep-femtech-and-the-fight-for-women-s-health-equity 2026-06-11T20:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-evolution-of-femtech-from-menstrual-tracking-to-deep-femtech-and-the-fight-for-women-s-health-equity 2026-06-11T20:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/denisovan-dna-continues-to-shape-human-immunity-and-skeletal-development-yale-led-study-reveals 2026-06-11T20:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denisovan-dna-continues-to-shape-human-immunity-and-skeletal-development-yale-led-study-reveals 2026-06-11T20:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-biopharma-and-joinn-biologics-forge-strategic-partnership-to-develop-daratumumab-biosimilar-xdarzane 2026-06-11T20:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xbrane-biopharma-and-joinn-biologics-forge-strategic-partnership-to-develop-daratumumab-biosimilar-xdarzane 2026-06-11T20:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/five-minute-finger-prick-syphilis-test-aims-to-protect-newborns-from-congenital-infection 2026-06-11T20:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-minute-finger-prick-syphilis-test-aims-to-protect-newborns-from-congenital-infection 2026-06-11T20:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-model-turns-blood-derived-episignatures-tissue-agnostic-advancing-prenatal-genetic-testing 2026-06-11T20:08:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-model-turns-blood-derived-episignatures-tissue-agnostic-advancing-prenatal-genetic-testing 2026-06-11T20:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/medical-associations-draw-red-lines-ai-must-remain-a-tool-not-a-replacement-for-physician-judgment 2026-06-11T19:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-associations-draw-red-lines-ai-must-remain-a-tool-not-a-replacement-for-physician-judgment 2026-06-11T19:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-healthcare-jobs-why-radiologists-are-thriving-despite-automation-predictions 2026-06-11T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-healthcare-jobs-why-radiologists-are-thriving-despite-automation-predictions 2026-06-11T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-reports-first-human-plague-death-of-2026-as-animal-cases-rise-across-two-counties 2026-06-11T19:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-reports-first-human-plague-death-of-2026-as-animal-cases-rise-across-two-counties 2026-06-11T19:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/nonprofit-acquires-discontinued-adc-luveltamab-tazevibulin-to-preserve-compassionate-use-access-for-children-with-ultra-rare-fatal-leukemia 2026-06-11T19:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nonprofit-acquires-discontinued-adc-luveltamab-tazevibulin-to-preserve-compassionate-use-access-for-children-with-ultra-rare-fatal-leukemia 2026-06-11T19:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/danaher-biotechnology-segment-posts-7-core-revenue-growth-in-q1-2026-driven-by-bioprocessing-momentum-and-mab-demand 2026-06-11T19:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danaher-biotechnology-segment-posts-7-core-revenue-growth-in-q1-2026-driven-by-bioprocessing-momentum-and-mab-demand 2026-06-11T19:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-lab-property-market-shows-early-recovery-signs-as-landlords-pivot-to-ai-and-biomanufacturing-tenants 2026-06-11T19:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-lab-property-market-shows-early-recovery-signs-as-landlords-pivot-to-ai-and-biomanufacturing-tenants 2026-06-11T19:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-cuts-clinician-diagnosed-long-covid-risk-by-50-in-activ-6-trial 2026-06-11T18:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-cuts-clinician-diagnosed-long-covid-risk-by-50-in-activ-6-trial 2026-06-11T18:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-x-ray-tools-to-be-rolled-out-across-all-nhs-trusts-in-england-by-2029-backed-by-ps20-million-government-investment 2026-06-11T18:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-x-ray-tools-to-be-rolled-out-across-all-nhs-trusts-in-england-by-2029-backed-by-ps20-million-government-investment 2026-06-11T18:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/the-obesity-inflammation-axis-how-incretin-immunotherapy-combinations-are-reshaping-autoimmune-disease-treatment 2026-06-11T18:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-obesity-inflammation-axis-how-incretin-immunotherapy-combinations-are-reshaping-autoimmune-disease-treatment 2026-06-11T18:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/new-genetic-driver-copa-identified-in-rare-small-intestinal-cancers-bypassing-canonical-wnt-pathway-mutations 2026-06-11T18:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-genetic-driver-copa-identified-in-rare-small-intestinal-cancers-bypassing-canonical-wnt-pathway-mutations 2026-06-11T18:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/marshall-university-board-approves-3-5m-site-acquisition-for-new-school-of-medicine-facility 2026-06-11T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marshall-university-board-approves-3-5m-site-acquisition-for-new-school-of-medicine-facility 2026-06-11T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/curium-peptidream-and-pdradiopharma-complete-patient-dosing-in-phase-2-trial-of-64cu-psma-i-t-pet-diagnostic-for-prostate-cancer-in-japan 2026-06-11T18:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curium-peptidream-and-pdradiopharma-complete-patient-dosing-in-phase-2-trial-of-64cu-psma-i-t-pet-diagnostic-for-prostate-cancer-in-japan 2026-06-11T18:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/ex-vivo-drug-profiling-reveals-dasatinib-sensitivity-in-p53-aberrant-refractory-lymphoid-malignancies 2026-06-11T17:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ex-vivo-drug-profiling-reveals-dasatinib-sensitivity-in-p53-aberrant-refractory-lymphoid-malignancies 2026-06-11T17:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/montara-therapeutics-strengthens-leadership-with-karuna-founder-andrew-miller-new-cmo-and-cto-promotion-to-advance-brain-selective-cns-platform 2026-06-11T17:09:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montara-therapeutics-strengthens-leadership-with-karuna-founder-andrew-miller-new-cmo-and-cto-promotion-to-advance-brain-selective-cns-platform 2026-06-11T17:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/texas-children-s-and-baylor-awarded-up-to-17-25-million-to-join-aria-impact-network-for-autism-clinical-trials 2026-06-11T17:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-children-s-and-baylor-awarded-up-to-17-25-million-to-join-aria-impact-network-for-autism-clinical-trials 2026-06-11T17:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/baystate-franklin-nurses-vote-98-to-reject-contract-offer-amid-layoffs-citing-patient-care-concerns 2026-06-11T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baystate-franklin-nurses-vote-98-to-reject-contract-offer-amid-layoffs-citing-patient-care-concerns 2026-06-11T17:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-s-new-rules-data-discipline-and-the-return-of-capital-in-2026 2026-06-11T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-s-new-rules-data-discipline-and-the-return-of-capital-in-2026 2026-06-11T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-resident-t-cells-and-dendritic-cells-form-in-situ-archetype-that-predicts-melanoma-immunotherapy-response 2026-06-11T17:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-resident-t-cells-and-dendritic-cells-form-in-situ-archetype-that-predicts-melanoma-immunotherapy-response 2026-06-11T17:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/propanc-biopharma-authorizes-5-million-share-repurchase-program-as-lead-candidate-prp-advances-toward-first-in-human-trial 2026-06-11T17:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/propanc-biopharma-authorizes-5-million-share-repurchase-program-as-lead-candidate-prp-advances-toward-first-in-human-trial 2026-06-11T17:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/continuous-environmental-monitoring-emerges-as-critical-pillar-of-biopharmaceutical-quality-assurance 2026-06-11T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuous-environmental-monitoring-emerges-as-critical-pillar-of-biopharmaceutical-quality-assurance 2026-06-11T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-tobacco-stock-holdings-and-industry-donations-surge-as-fda-eases-vaping-and-nicotine-pouch-standards 2026-06-11T16:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-tobacco-stock-holdings-and-industry-donations-surge-as-fda-eases-vaping-and-nicotine-pouch-standards 2026-06-11T16:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-certified-group-s-pfas-testing-method-for-seafood-addressing-import-alert-99-48 2026-06-11T16:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-certified-group-s-pfas-testing-method-for-seafood-addressing-import-alert-99-48 2026-06-11T16:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-trial-design-undergoes-rapid-transformation-as-ctdna-mrd-and-advanced-imaging-move-to-primary-endpoints 2026-06-11T16:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-trial-design-undergoes-rapid-transformation-as-ctdna-mrd-and-advanced-imaging-move-to-primary-endpoints 2026-06-11T16:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-institute-for-cancer-research-secures-9-4-million-nci-renewal-to-sustain-nearly-50-years-of-basic-laboratory-cancer-research 2026-06-11T16:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-institute-for-cancer-research-secures-9-4-million-nci-renewal-to-sustain-nearly-50-years-of-basic-laboratory-cancer-research 2026-06-11T16:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/ou-health-launches-oklahoma-s-first-ai-powered-adaptive-radiation-therapy-system 2026-06-11T16:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ou-health-launches-oklahoma-s-first-ai-powered-adaptive-radiation-therapy-system 2026-06-11T16:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/psyeval-benchmark-reveals-ai-models-still-fall-short-on-clinical-judgment-and-empathy-in-mental-health-care 2026-06-11T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psyeval-benchmark-reveals-ai-models-still-fall-short-on-clinical-judgment-and-empathy-in-mental-health-care 2026-06-11T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/uae-becomes-first-country-worldwide-to-approve-astrazeneca-s-oral-serd-camizestrant-for-esr1-mutant-breast-cancer 2026-06-11T16:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uae-becomes-first-country-worldwide-to-approve-astrazeneca-s-oral-serd-camizestrant-for-esr1-mutant-breast-cancer 2026-06-11T16:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/an-immunologist-who-grew-up-unvaccinated-argues-empathy-not-facts-alone-is-key-to-overcoming-vaccine-hesitancy 2026-06-11T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an-immunologist-who-grew-up-unvaccinated-argues-empathy-not-facts-alone-is-key-to-overcoming-vaccine-hesitancy 2026-06-11T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/palisade-bio-strengthens-board-with-biotech-veterans-baltera-and-zwick-as-pali-2108-advances-toward-phase-2-in-ibd 2026-06-11T15:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palisade-bio-strengthens-board-with-biotech-veterans-baltera-and-zwick-as-pali-2108-advances-toward-phase-2-in-ibd 2026-06-11T15:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/a-star-and-nus-launch-joint-synthetic-biology-lab-to-accelerate-bioeconomy-translation 2026-06-11T15:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-star-and-nus-launch-joint-synthetic-biology-lab-to-accelerate-bioeconomy-translation 2026-06-11T15:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-zbp1-how-a-cellular-alarm-system-could-overcome-cancer-immunotherapy-resistance 2026-06-11T15:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-zbp1-how-a-cellular-alarm-system-could-overcome-cancer-immunotherapy-resistance 2026-06-11T15:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/lumito-appoints-pascal-bamford-as-chair-of-scientific-advisory-board-adds-spatial-biology-and-biomarker-experts-to-advance-scizys-platform 2026-06-11T15:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumito-appoints-pascal-bamford-as-chair-of-scientific-advisory-board-adds-spatial-biology-and-biomarker-experts-to-advance-scizys-platform 2026-06-11T15:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/horizon-europe-funds-combascale-community-health-workers-to-tackle-cardiovascular-hiv-and-tb-care-in-lesotho 2026-06-11T15:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/horizon-europe-funds-combascale-community-health-workers-to-tackle-cardiovascular-hiv-and-tb-care-in-lesotho 2026-06-11T15:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-wave-neuroscience-s-mert-system-first-personalized-biomarker-guided-neuromodulation-platform-for-ptsd 2026-06-11T15:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-wave-neuroscience-s-mert-system-first-personalized-biomarker-guided-neuromodulation-platform-for-ptsd 2026-06-11T15:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-mapping-study-identifies-liver-enzyme-ces1-as-key-driver-of-cocaine-addiction-opening-new-therapeutic-avenues 2026-06-11T15:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-mapping-study-identifies-liver-enzyme-ces1-as-key-driver-of-cocaine-addiction-opening-new-therapeutic-avenues 2026-06-11T15:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-crispr-screening-with-perturb-dbit-redefines-preclinical-oncology-target-validation 2026-06-11T15:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-crispr-screening-with-perturb-dbit-redefines-preclinical-oncology-target-validation 2026-06-11T15:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/structure-of-the-argonaute-maturation-complex-guides-rational-rna-therapeutic-design 2026-06-11T15:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-of-the-argonaute-maturation-complex-guides-rational-rna-therapeutic-design 2026-06-11T15:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-lipid-mapping-reveals-psychosine-buildup-patterns-in-krabbe-disease-opening-new-therapeutic-targeting-strategies 2026-06-11T15:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-lipid-mapping-reveals-psychosine-buildup-patterns-in-krabbe-disease-opening-new-therapeutic-targeting-strategies 2026-06-11T15:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/harrow-re-launches-verkazia-first-fda-approved-steroid-sparing-therapy-for-vernal-keratoconjunctivitis 2026-06-11T15:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harrow-re-launches-verkazia-first-fda-approved-steroid-sparing-therapy-for-vernal-keratoconjunctivitis 2026-06-11T15:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/eirgenix-advances-dual-track-biosimilar-and-cdmo-strategy-targeting-her2-positive-breast-cancer-and-global-supply-chain-opportunities 2026-06-11T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eirgenix-advances-dual-track-biosimilar-and-cdmo-strategy-targeting-her2-positive-breast-cancer-and-global-supply-chain-opportunities 2026-06-11T15:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-submits-ind-for-first-of-its-kind-genomics-enabled-phase-2a-trial-of-teverelix-in-endometriosis 2026-06-11T15:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-submits-ind-for-first-of-its-kind-genomics-enabled-phase-2a-trial-of-teverelix-in-endometriosis 2026-06-11T15:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/flexible-trial-execution-blending-site-based-and-at-home-models-without-compromising-quality-upcoming-xtalks-webinar 2026-06-11T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flexible-trial-execution-blending-site-based-and-at-home-models-without-compromising-quality-upcoming-xtalks-webinar 2026-06-11T15:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/fleming-initiative-and-cepheid-launch-landmark-trace-cpe-study-to-evaluate-rapid-molecular-screening-for-drug-resistant-infections-in-nhs-hospitals 2026-06-11T14:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fleming-initiative-and-cepheid-launch-landmark-trace-cpe-study-to-evaluate-rapid-molecular-screening-for-drug-resistant-infections-in-nhs-hospitals 2026-06-11T14:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/tap-water-may-be-the-safest-choice-for-enteric-coated-medications-study-finds 2026-06-11T13:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tap-water-may-be-the-safest-choice-for-enteric-coated-medications-study-finds 2026-06-11T13:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/senate-investigation-reveals-spotify-removed-over-57000-podcasts-promoting-illegal-opioids-and-prescription-drugs 2026-06-11T13:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-investigation-reveals-spotify-removed-over-57000-podcasts-promoting-illegal-opioids-and-prescription-drugs 2026-06-11T13:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/merck-animal-health-to-acquire-targan-gaining-high-speed-biodevice-technology-for-poultry-operations 2026-06-11T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-animal-health-to-acquire-targan-gaining-high-speed-biodevice-technology-for-poultry-operations 2026-06-11T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/phosphatidylcholine-loss-identified-as-reversible-driver-of-mitochondrial-aging 2026-06-11T12:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phosphatidylcholine-loss-identified-as-reversible-driver-of-mitochondrial-aging 2026-06-11T12:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/urinary-mmp-1-identified-as-potential-biomarker-for-calcium-oxalate-kidney-stone-disease 2026-06-11T12:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urinary-mmp-1-identified-as-potential-biomarker-for-calcium-oxalate-kidney-stone-disease 2026-06-11T12:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-new-drug-portfolio-drives-revenue-momentum-and-analyst-upgrades 2026-06-11T12:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-new-drug-portfolio-drives-revenue-momentum-and-analyst-upgrades 2026-06-11T12:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/reframing-immune-thrombocytopenia-the-push-to-look-beyond-platelet-counts-in-clinical-research-and-drug-development 2026-06-11T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reframing-immune-thrombocytopenia-the-push-to-look-beyond-platelet-counts-in-clinical-research-and-drug-development 2026-06-11T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/stallergenes-greer-to-present-paediatric-phase-iii-yobi-data-and-real-world-efficapsi-findings-at-eaaci-2026 2026-06-11T10:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stallergenes-greer-to-present-paediatric-phase-iii-yobi-data-and-real-world-efficapsi-findings-at-eaaci-2026 2026-06-11T10:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stock-investing-101-a-framework-for-navigating-the-high-stakes-drug-development-sector 2026-06-11T10:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-stock-investing-101-a-framework-for-navigating-the-high-stakes-drug-development-sector 2026-06-11T10:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/yale-secret-shopper-study-finds-92-of-online-websites-prescribe-glp-1-drugs-with-minimal-clinician-oversight 2026-06-11T10:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-secret-shopper-study-finds-92-of-online-websites-prescribe-glp-1-drugs-with-minimal-clinician-oversight 2026-06-11T10:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-resubmission-of-camurus-cam2029-nda-for-acromegaly-sets-december-2026-pdufa-date 2026-06-11T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-resubmission-of-camurus-cam2029-nda-for-acromegaly-sets-december-2026-pdufa-date 2026-06-11T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-adaptation-mechanisms-driving-therapy-resistance-in-gastrointestinal-malignancies-a-new-research-initiative 2026-06-11T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-adaptation-mechanisms-driving-therapy-resistance-in-gastrointestinal-malignancies-a-new-research-initiative 2026-06-11T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-supreme-court-upholds-policy-protecting-drug-exposed-newborns-rejecting-aclu-challenge 2026-06-11T08:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-supreme-court-upholds-policy-protecting-drug-exposed-newborns-rejecting-aclu-challenge 2026-06-11T08:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/epigenetic-editing-emerges-as-a-precision-strategy-to-overcome-cancer-therapy-resistance 2026-06-11T08:08:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epigenetic-editing-emerges-as-a-precision-strategy-to-overcome-cancer-therapy-resistance 2026-06-11T08:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/disentangling-menopause-and-aging-in-women-with-multiple-sclerosis-new-research-targets-midlife-disease-progression 2026-06-11T08:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disentangling-menopause-and-aging-in-women-with-multiple-sclerosis-new-research-targets-midlife-disease-progression 2026-06-11T08:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/nat10-inhibition-alleviates-renal-tubular-epithelial-cell-senescence-by-impeding-ac4c-modification 2026-06-11T08:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nat10-inhibition-alleviates-renal-tubular-epithelial-cell-senescence-by-impeding-ac4c-modification 2026-06-11T08:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-single-trial-default-reshapes-drug-development-what-the-february-2026-policy-means-for-sponsors-and-sites 2026-06-11T08:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-single-trial-default-reshapes-drug-development-what-the-february-2026-policy-means-for-sponsors-and-sites 2026-06-11T08:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/hyundai-bioscience-offers-free-xafty-r-supply-and-trial-funding-to-who-for-ebola-emergency-response 2026-06-11T08:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyundai-bioscience-offers-free-xafty-r-supply-and-trial-funding-to-who-for-ebola-emergency-response 2026-06-11T08:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-achieve-global-first-rna-editing-technology-leaper-enters-clinical-trials-for-duchenne-muscular-dystrophy 2026-06-11T08:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-achieve-global-first-rna-editing-technology-leaper-enters-clinical-trials-for-duchenne-muscular-dystrophy 2026-06-11T08:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/ustr-launches-section-301-investigation-into-germany-s-pharmaceutical-pricing-policies 2026-06-11T07:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ustr-launches-section-301-investigation-into-germany-s-pharmaceutical-pricing-policies 2026-06-11T07:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-central-sensitization-neuromodulation-emerges-as-a-precision-strategy-for-knee-osteoarthritis-pain 2026-06-11T06:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-central-sensitization-neuromodulation-emerges-as-a-precision-strategy-for-knee-osteoarthritis-pain 2026-06-11T06:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-del-brax-hits-primary-biomarker-endpoint-in-phase-i-ii-fshd-trial-paving-way-for-first-disease-modifying-therapy 2026-06-11T06:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-del-brax-hits-primary-biomarker-endpoint-in-phase-i-ii-fshd-trial-paving-way-for-first-disease-modifying-therapy 2026-06-11T06:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/urine-liquid-biopsy-shows-strong-promise-for-guiding-bladder-cancer-treatment-clinical-trials-on-the-horizon 2026-06-11T06:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urine-liquid-biopsy-shows-strong-promise-for-guiding-bladder-cancer-treatment-clinical-trials-on-the-horizon 2026-06-11T06:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/china-emerges-as-a-global-hub-for-affordable-car-t-therapy-drawing-foreign-patients-with-advanced-cancer-care 2026-06-11T04:55:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-emerges-as-a-global-hub-for-affordable-car-t-therapy-drawing-foreign-patients-with-advanced-cancer-care 2026-06-11T04:55:07+00:00 hourly 0.9 https://trial.medpath.com/news/scribe-therapeutics-files-for-ipo-to-advance-gene-editing-pipeline-for-cardiometabolic-disorders 2026-06-11T04:55:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scribe-therapeutics-files-for-ipo-to-advance-gene-editing-pipeline-for-cardiometabolic-disorders 2026-06-11T04:55:06+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-uncover-self-reinforcing-immune-loop-driving-sjogren-s-disease-progression 2026-06-11T04:55:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-uncover-self-reinforcing-immune-loop-driving-sjogren-s-disease-progression 2026-06-11T04:55:05+00:00 hourly 0.9 https://trial.medpath.com/news/dee-market-to-surge-almost-12-annually-on-gene-therapy-advances 2026-06-11T04:55:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dee-market-to-surge-almost-12-annually-on-gene-therapy-advances 2026-06-11T04:55:03+00:00 hourly 0.9 https://trial.medpath.com/news/jw-pharmaceutical-s-ddc-02-restores-cognitive-function-across-multiple-rare-neurodevelopmental-disorder-models-targets-2028-clinical-trials 2026-06-11T03:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jw-pharmaceutical-s-ddc-02-restores-cognitive-function-across-multiple-rare-neurodevelopmental-disorder-models-targets-2028-clinical-trials 2026-06-11T03:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-lays-off-103-employees-in-fifth-round-of-cuts-since-mid-2025-three-vps-among-casualties 2026-06-11T03:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-lays-off-103-employees-in-fifth-round-of-cuts-since-mid-2025-three-vps-among-casualties 2026-06-11T03:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/gc-pharma-unveils-ai-driven-mrna-lnp-platform-advances-covid-19-vaccine-toward-phase-2-trial 2026-06-11T03:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-pharma-unveils-ai-driven-mrna-lnp-platform-advances-covid-19-vaccine-toward-phase-2-trial 2026-06-11T03:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/virtual-second-opinions-drive-meaningful-treatment-changes-for-one-third-of-cancer-patients 2026-06-11T02:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virtual-second-opinions-drive-meaningful-treatment-changes-for-one-third-of-cancer-patients 2026-06-11T02:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/glyconex-doses-first-patient-in-phase-i-trial-of-glycan-directed-adc-gnx1021-for-advanced-solid-tumors 2026-06-11T02:07:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glyconex-doses-first-patient-in-phase-i-trial-of-glycan-directed-adc-gnx1021-for-advanced-solid-tumors 2026-06-11T02:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-researchers-launch-data-dashboard-to-track-colorado-s-912-million-opioid-settlement-spending 2026-06-11T02:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-researchers-launch-data-dashboard-to-track-colorado-s-912-million-opioid-settlement-spending 2026-06-11T02:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/body-clock-drives-circadian-rhythm-in-post-meal-calorie-burning-mass-general-brigham-study-reveals 2026-06-11T01:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/body-clock-drives-circadian-rhythm-in-post-meal-calorie-burning-mass-general-brigham-study-reveals 2026-06-11T01:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/frost-sullivan-global-pharma-enters-decisive-reset-as-ai-biologics-and-supply-resilience-redefine-growth-through-2031 2026-06-11T01:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/frost-sullivan-global-pharma-enters-decisive-reset-as-ai-biologics-and-supply-resilience-redefine-growth-through-2031 2026-06-11T01:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-s-isaralgagene-civaparvovec-nears-accelerated-approval-as-fabry-disease-market-poised-to-reach-5-92-billion-by-2035 2026-06-11T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-s-isaralgagene-civaparvovec-nears-accelerated-approval-as-fabry-disease-market-poised-to-reach-5-92-billion-by-2035 2026-06-11T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/aga-guideline-panel-declines-to-endorse-ai-assisted-colonoscopy-citing-lack-of-survival-benefit 2026-06-11T00:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aga-guideline-panel-declines-to-endorse-ai-assisted-colonoscopy-citing-lack-of-survival-benefit 2026-06-11T00:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/dietary-methionine-restriction-remodels-chromatin-and-extends-survival-in-glioma-models 2026-06-11T00:08:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dietary-methionine-restriction-remodels-chromatin-and-extends-survival-in-glioma-models 2026-06-11T00:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-mexico-triples-local-growth-pushes-obesity-destigmatization-and-public-sector-access 2026-06-11T00:07:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-mexico-triples-local-growth-pushes-obesity-destigmatization-and-public-sector-access 2026-06-11T00:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/cross-species-single-cell-atlas-reveals-conserved-and-divergent-programs-in-mammalian-fetal-ovarian-development 2026-06-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cross-species-single-cell-atlas-reveals-conserved-and-divergent-programs-in-mammalian-fetal-ovarian-development 2026-06-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-first-hospital-based-biomedical-engineering-research-centre-opens-in-melbourne 2026-06-10T23:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-s-first-hospital-based-biomedical-engineering-research-centre-opens-in-melbourne 2026-06-10T23:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-triple-negative-breast-cancer-from-preventive-vaccines-to-adc-approvals-reshape-the-treatment-landscape 2026-06-10T23:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-triple-negative-breast-cancer-from-preventive-vaccines-to-adc-approvals-reshape-the-treatment-landscape 2026-06-10T23:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-appoints-timothy-coughlin-to-board-of-directors-amid-pipeline-advancement 2026-06-10T23:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-appoints-timothy-coughlin-to-board-of-directors-amid-pipeline-advancement 2026-06-10T23:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/the-rise-of-ai-para-therapy-nearly-one-in-five-young-adults-now-use-chatbots-for-mental-health-raising-clinical-and-regulatory-concerns 2026-06-10T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-rise-of-ai-para-therapy-nearly-one-in-five-young-adults-now-use-chatbots-for-mental-health-raising-clinical-and-regulatory-concerns 2026-06-10T22:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-oncology-in-practice-scaling-personalized-cancer-care-through-genomics-ctdna-and-systemwide-integration 2026-06-10T22:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-oncology-in-practice-scaling-personalized-cancer-care-through-genomics-ctdna-and-systemwide-integration 2026-06-10T22:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-drug-delivery-devices-market-to-reach-1-06-trillion-by-2032-driven-by-biologics-boom-and-smart-device-innovation 2026-06-10T22:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-drug-delivery-devices-market-to-reach-1-06-trillion-by-2032-driven-by-biologics-boom-and-smart-device-innovation 2026-06-10T22:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/mexico-launches-30-day-fast-track-approval-for-strategic-pharmaceutical-and-medical-device-investments 2026-06-10T22:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mexico-launches-30-day-fast-track-approval-for-strategic-pharmaceutical-and-medical-device-investments 2026-06-10T22:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/brain-health-care-accelerator-model-redefines-dementia-diagnosis-and-treatment-in-primary-care 2026-06-10T21:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-health-care-accelerator-model-redefines-dementia-diagnosis-and-treatment-in-primary-care 2026-06-10T21:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/brain-health-can-improve-into-your-90s-landmark-three-year-study-finds 2026-06-10T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-health-can-improve-into-your-90s-landmark-three-year-study-finds 2026-06-10T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-generated-synthetic-real-world-data-shows-promise-for-accelerating-cancer-clinical-trials 2026-06-10T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-generated-synthetic-real-world-data-shows-promise-for-accelerating-cancer-clinical-trials 2026-06-10T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-pharma-leaders-warn-of-innovation-access-crisis-as-mfn-pricing-and-cost-containment-pressure-mount 2026-06-10T21:08:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-pharma-leaders-warn-of-innovation-access-crisis-as-mfn-pricing-and-cost-containment-pressure-mount 2026-06-10T21:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/usp-report-drug-shortages-decline-23-in-2025-but-average-duration-stretches-to-5-3-years 2026-06-10T20:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usp-report-drug-shortages-decline-23-in-2025-but-average-duration-stretches-to-5-3-years 2026-06-10T20:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-vs-pfizer-obesity-week-presentations-highlight-diverging-strategies-in-metabolic-disease 2026-06-10T20:13:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-vs-pfizer-obesity-week-presentations-highlight-diverging-strategies-in-metabolic-disease 2026-06-10T20:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/florida-physician-and-staff-charged-in-alleged-clinical-trial-data-falsification-scheme 2026-06-10T20:13:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-physician-and-staff-charged-in-alleged-clinical-trial-data-falsification-scheme 2026-06-10T20:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-glue-degraders-of-hur-suppress-braf-mutant-colorectal-cancer 2026-06-10T20:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-glue-degraders-of-hur-suppress-braf-mutant-colorectal-cancer 2026-06-10T20:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/patient-narratives-highlight-md-anderson-s-multidisciplinary-approach-in-ovarian-cancer-and-rare-skull-base-tumor-care 2026-06-10T20:12:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-narratives-highlight-md-anderson-s-multidisciplinary-approach-in-ovarian-cancer-and-rare-skull-base-tumor-care 2026-06-10T20:12:17+00:00 hourly 0.9 https://trial.medpath.com/news/vivos-therapeutics-and-south-palm-cardiovascular-associates-finalize-agreements-to-launch-south-florida-sleep-airway-medicine-center 2026-06-10T20:12:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivos-therapeutics-and-south-palm-cardiovascular-associates-finalize-agreements-to-launch-south-florida-sleep-airway-medicine-center 2026-06-10T20:12:11+00:00 hourly 0.9 https://trial.medpath.com/news/americans-trust-in-cdc-plummets-to-50-amid-political-polarization-harvard-poll-reveals 2026-06-10T20:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/americans-trust-in-cdc-plummets-to-50-amid-political-polarization-harvard-poll-reveals 2026-06-10T20:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/allergan-aesthetics-unveils-layered-beauty-report-charting-a-global-shift-toward-personalized-long-term-aesthetic-care 2026-06-10T20:11:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allergan-aesthetics-unveils-layered-beauty-report-charting-a-global-shift-toward-personalized-long-term-aesthetic-care 2026-06-10T20:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/pharmac-s-diabetes-drug-access-overhaul-under-fire-no-maori-impact-modelling-conducted 2026-06-10T19:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmac-s-diabetes-drug-access-overhaul-under-fire-no-maori-impact-modelling-conducted 2026-06-10T19:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/how-basket-trials-are-reshaping-drug-development-timelines-for-rare-pediatric-diseases 2026-06-10T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-basket-trials-are-reshaping-drug-development-timelines-for-rare-pediatric-diseases 2026-06-10T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-apptec-added-to-pentagon-s-chinese-military-companies-list-raising-supply-chain-concerns-for-us-pharma 2026-06-10T19:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-apptec-added-to-pentagon-s-chinese-military-companies-list-raising-supply-chain-concerns-for-us-pharma 2026-06-10T19:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/fsu-awards-250000-in-inaugural-clinical-catalyst-grants-to-advance-healthcare-innovation 2026-06-10T19:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fsu-awards-250000-in-inaugural-clinical-catalyst-grants-to-advance-healthcare-innovation 2026-06-10T19:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/brain-injury-survivors-face-1-75-fold-higher-brain-cancer-mortality-risk-landmark-37-year-study-finds 2026-06-10T18:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-injury-survivors-face-1-75-fold-higher-brain-cancer-mortality-risk-landmark-37-year-study-finds 2026-06-10T18:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/research-council-of-finland-awards-eur79-million-for-biosciences-health-and-environment-research-including-key-drug-development-and-disease-projects 2026-06-10T18:10:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-council-of-finland-awards-eur79-million-for-biosciences-health-and-environment-research-including-key-drug-development-and-disease-projects 2026-06-10T18:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/vmd-reports-58-accidental-human-exposures-to-librela-18-to-solensia-in-uk-pharmacovigilance-data 2026-06-10T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vmd-reports-58-accidental-human-exposures-to-librela-18-to-solensia-in-uk-pharmacovigilance-data 2026-06-10T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-propose-first-principle-of-drug-design-with-novel-pulsatile-fxr-agonist-linafexor 2026-06-10T18:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-propose-first-principle-of-drug-design-with-novel-pulsatile-fxr-agonist-linafexor 2026-06-10T18:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/closing-the-gap-between-biotech-innovation-and-patient-access-america-s-next-healthcare-challenge 2026-06-10T18:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/closing-the-gap-between-biotech-innovation-and-patient-access-america-s-next-healthcare-challenge 2026-06-10T18:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/abtherx-expands-atlastm-platform-with-vhh-single-domain-antibody-technology-and-lambda-common-light-chains-to-tackle-multispecifics-and-undruggable-targets 2026-06-10T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abtherx-expands-atlastm-platform-with-vhh-single-domain-antibody-technology-and-lambda-common-light-chains-to-tackle-multispecifics-and-undruggable-targets 2026-06-10T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/immunic-highlights-imu-856-discovery-at-efmc-acsmedi-symposium-as-oral-ms-therapy-nears-phase-3-readout 2026-06-10T18:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunic-highlights-imu-856-discovery-at-efmc-acsmedi-symposium-as-oral-ms-therapy-nears-phase-3-readout 2026-06-10T18:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/immunocon-2026-lg-sinha-calls-for-deeper-research-into-immunotherapy-cardiotoxicity-highlights-80-cardiac-event-rate 2026-06-10T18:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocon-2026-lg-sinha-calls-for-deeper-research-into-immunotherapy-cardiotoxicity-highlights-80-cardiac-event-rate 2026-06-10T18:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/incidental-ct-finding-leads-to-early-lung-cancer-diagnosis-in-young-non-smoker 2026-06-10T18:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incidental-ct-finding-leads-to-early-lung-cancer-diagnosis-in-young-non-smoker 2026-06-10T18:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/agentic-ai-as-the-oncologist-s-deputy-vanderbilt-s-four-agent-system-aims-to-eliminate-guesswork-in-cancer-treatment-decisions 2026-06-10T17:11:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agentic-ai-as-the-oncologist-s-deputy-vanderbilt-s-four-agent-system-aims-to-eliminate-guesswork-in-cancer-treatment-decisions 2026-06-10T17:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-limerick-to-lead-eur60-million-rinn-pharma-biopharma-research-centre-for-next-generation-medicines 2026-06-10T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-limerick-to-lead-eur60-million-rinn-pharma-biopharma-research-centre-for-next-generation-medicines 2026-06-10T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/n-zyme-biomedical-launches-phase-2-trial-of-first-pepsin-inhibitor-for-laryngopharyngeal-reflux-secures-4-6m-series-a 2026-06-10T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n-zyme-biomedical-launches-phase-2-trial-of-first-pepsin-inhibitor-for-laryngopharyngeal-reflux-secures-4-6m-series-a 2026-06-10T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/uc-irvine-s-oswald-steward-awarded-2026-kavli-prize-in-neuroscience-for-discovery-of-local-protein-translation-in-neurons 2026-06-10T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-irvine-s-oswald-steward-awarded-2026-kavli-prize-in-neuroscience-for-discovery-of-local-protein-translation-in-neurons 2026-06-10T17:08:27+00:00 hourly 0.9